Cutaneous Melanoma. Population-based studies on epidemiological and clinical aspects by Waal, A.C. de
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/143491
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Paranimfen
Marieke Schouwink
mariekeschouwink@hotmail.com
Leonard Wetzels
ljaawetzels@hotmail.com
Uitnodiging 
voor het bijwonen van 
de openbare verdediging
van het proefschrift 
CUTANEOUS
MELANOMA
POPULATION- BASED 
STUDIES ON
EPIDEMIOLOGICAL  
AND CLINICAL ASPECTS
op woensdag 16 september 2015 
om 14.30 precies in de aula van 
de Radboud Universiteit Nijmegen
Comeniuslaan 2 te Nijmegen.
U bent van harte welkom  
bij deze plechtigheid en de  
aansluitende receptie ter plaatse.
Anne de Waal
Anne.deWaal@radboudumc.nl
Anne de Waal
CUTANEOUS 
MELANOMA
POPULATION- BASED 
STUDIES ON
EPIDEMIOLOGICAL  
AND CLINICAL ASPECTS
C
U
TA
N
E
O
U
S
 M
E
L
A
N
O
M
A
  |  A
N
N
E
 D
E
 W
A
A
L
CUTANEOUS MELANOMA
POPULATION-BASED STUDIES ON
EPIDEMIOLOGICAL AND CLINICAL ASPECTS
Anne de Waal
Proefschrift
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. Th.L.M. Engelen, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen op woensdag 16 september 2015 
om 14.30 uur precies
door
Anne Carolien de Waal
geboren op 3 augustus 1983
te Culemborg
ISBN
978-94-6259-750-1
Cover  
Photo: Anne de Waal
Design/lay-out  
Promotie In Zicht, Arnhem
Print
Ipskamp Drukkers, Enschede
The work presented in this thesis was carried out within 
the Radboud Institute for Health Sciences
© 2015, A.C. de Waal 
All rights are reserved. No part of this book may be reproduced, distributed, stored in a retrieval system,  
or transmitted in any form or by any means, without prior written permission of the author.
CUTANEOUS MELANOMA
POPULATION-BASED STUDIES ON
EPIDEMIOLOGICAL AND CLINICAL ASPECTS
Promotor
 Prof. dr. L.A.L.M. Kiemeney  
Copromotoren 
 Dr. K.K.H. Aben
 Dr. M.M. van Rossum 
Manuscriptcommissie 
 Prof. dr. W.R. Gerritsen
 Prof. dr. P. Wesseling
 Dr. N.A. Kukutsch (LUMC)
Voor mijn ouders
Contents
Chapter 1 General introduction and thesis outline 9
Part I | Epidemiological aspects 29
Chapter 2 Melanoma of unknown primary origin 
Eur J Cancer. 2013 Feb;49(3):676-83.
31
Chapter 3 Reproducibility of self-reported melanoma risk factors  
in melanoma patients 
Melanoma Res. 2014 Dec;24(6):592-601.
49
Chapter 4 Risk factors for second primary melanoma
Submitted
73
Part II | Clinical aspects 91
Chapter 5 Impact of mitotic activity on the pathological substaging  
of pT1 melanoma 
Br J Dermatol. 2014 Apr; 170(4):874-7.
93
Chapter 6 Histopathological examination of re-excision specimens  
of completely excised melanomas 
Virchows Arch. 2014 Aug;465(2):225-31. 
103
Chapter 7 General discussion and future perspectives 119
Summary
Samenvatting
List of publications
PhD Portfolio
Curriculum vitae
Dankwoord
135
139
143
145
147
149
GENERAL INTRODUCTION 
AND THESIS OUTLINE
1
11
GENERAL INTRODUCTION AND THESIS OUTLINE
1
1.1  Epidemiology
Cutaneous melanoma is a malignant tumour of melanocytes, a cell type present in 
the basal layer of the epidermis of the skin. It is one of the most aggressive types 
of skin cancer and its incidence is still increasing in most countries worldwide [1-3]. 
In the Netherlands, approximately 5,300 new cases of invasive melanoma were 
diagnosed in 2012, compared to 1,700 cases in 1989 (source: Netherlands Cancer 
Registry, see Fig. 1). The incidence is increasing across all disease stages for more 
than two decades, which indicates that this observation is not (only) due to earlier 
detection [2, 4]. About 800 persons die from melanoma each year in the Netherlands. 
The mortality rate has increased slightly until 2009 with an indication of stabilisation 
from 2010 onwards (source: Netherlands Cancer Registry), possibly due to recent 
improvements in the treatment of stage IV melanoma (see 1.4 Treatment).
Cutaneous melanoma occurs across all age groups, with a peak around 60-64 
years. In the Netherlands, the incidence in females is higher than in males (see Fig. 
1), like in most other European countries. In some Eastern European countries, 
however, males have a higher incidence [3]. In the United States and Australia, males 
are also affected more often [5]. Since the male:female ratio varies so much across 
countries, it is difficult to find an explanation, and not many studies are published on 
Figure 1 Incidence and mortality rates of invasive cutaneous melanoma in the Netherlands 
by gender (European Standardized Rates). Source: the Netherlands Cancer Registry, held by 
the Netherlands Comprehensive Cancer Organisation © May 2014.
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Tumour features have been compared between genders. No clear differences have 
been found in mitotic rate [22] or in mutation rates of important tumour genes, such 
as BRAF, NRAS, or KIT [23-29]. Hormonal differences between genders have also 
been investigated. Estrogens do not seem to influence the prognosis in melanoma 
[30, 31]. In addition, many studies show that after menopause, females still have a 
better survival [8-10, 21, 32-34], whereas some studies do show that the difference 
becomes smaller after menopause [12, 20, 23, 35-37]. Other mechanisms that differ 
between genders, and could play a role in melanoma prognosis, have been studied: 
gender differences in immune response [38, 39], the lower ability of males to 
neutralise reactive oxygen species [40], higher expression of matrix metalloprotein-
ases (MMPs) in males [41, 42], and a more profound relation between obesity and 
melanoma in males [43-45]. These studies still do not fully explain the survival 
difference. Likely, multiple factors are accountable for the female survival advantage.
1.2 Aetiology
The aetiology of melanoma is thought to be multifactorial and highly complex: genetic 
and environmental factors, and interactions between them, are thought to be relevant.
Risk factors for melanoma include having fair skin, red hair, high freckle density or 
high (dysplastic) nevus counts, family history of melanoma and immune suppression 
[46-54]. Furthermore, intermittent sun exposure, rather than cumulative sun exposure, 
and sun burns during childhood and adolescence are associated with a higher risk 
of melanoma [55-62]. Interactions between these factors are likely. For example, a 
person with fair skin will experience higher risks from sun burns than someone with a 
darker complexion.
About 10% of melanoma cases occur in families in which hereditary, high-penetrance 
mutations in the germline DNA are responsible [63]. Most frequent is a mutation in 
the CDKN2A gene, which is responsible for approximately 20 to 40% of melanomas 
occurring in families [64-66]. CDK4 is another well known, but much rarer familial 
melanoma gene [67]. Other, more recently discovered mutated genes that may 
cause familial melanoma include BAP1 [68], TERT [69] POT1 [70], and MITF [71], but 
these account for a minority of familial melanoma cases. The remainder of familial 
melanoma genes have not been identified yet, and it is believed that there are 
numerous.
 Non-familial or ‘sporadic’ melanoma cases likely occur due to a combination 
of genetic and environmental factors. Candidate gene studies and genome-wide 
association studies (GWAS) have shown that several low- to medium-penetrance 
this subject. Liu et al. recently reported that in the United States and Nordic countries, 
females have a higher incidence in age groups younger than 44 and males have a 
higher incidence after age 44 [6]. This pattern seems to be present in the Dutch 
population as well (see Fig. 2). Because this effect was not observed for non-melanoma 
skin cancer, Liu et al. posed that melanoma risk must also be dependent on other 
factors such as endocrine factors. However, a review including a pooled analysis of 
previous studies found no convincing evidence for the effect of endogenous or 
exogenous hormones on melanoma risk [7].
The prognosis of melanoma patients is worse in males [8-10]. Several researchers 
have studied this marked difference in survival between genders, but it has not been 
fully unravelled [11]. Breslow thickness of the primary melanoma, one of the most 
important prognostic factors, is often found to be thinner in women [10, 12]. This has 
been linked to different behaviour or awareness, causing women to detect their 
melanomas at an earlier stage. For example, females are more likely to participate in 
screening programs [13, 14], and males are generally more reluctant to consult a 
doctor [15, 16]. Furthermore, females have a higher awareness of skin cancer risk [17, 
18]. Body site may also play a role in the earlier detection: males have more 
melanomas on the trunk, while females have more melanomas on extremities [8, 10, 
12, 19, 20]. When adjusting for Breslow thickness and body site, only part of the 
difference in survival is explained [10, 21].
Figure 2  Age distribution of melanoma patients diagnosed in the Netherlands in 1989-2012 
according to gender. Source: the Netherlands Cancer Registry, held by the Netherlands 
Comprehensive Cancer Organisation © May 2014.
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1.3 Diagnosis 
When a melanoma is suspected, usually a diagnostic excision is performed first. This 
excision specimen is examined by a pathologist - preferably someone with experience 
in the examination of melanocytic skin lesions. Histologically, melanomas can be 
distinguished from common or dysplastic nevi by the following features: asymmetry, 
a lack of cellular maturation, atypical melanocytes with pleomorphic nuclei, a 
pagetoid growth pattern (neoplastic melanocytes scattered through the epidermis), 
mitotic figures, unequally sized nests of melanocytes, streaks of melanocytes in the 
dermis, signs of regression, and dusty melanin pigment within tumour cells [105]. 
genes are associated with melanoma. Some of the genes are related to pigmentation 
[72-76], some to nevus density [77-79] and others to DNA repair [80]. For some other 
identified genes the roles remain unclear [81, 82]. A clear example of a gene both 
related to melanoma and pigmentation, is the MC1R gene, associated with the red 
hair phenotype. See Table 1 for an overview of identified genetic loci associated with 
melanoma risk.
Ultraviolet radiation also plays a major role in the development of melanoma. Mainly 
ultraviolet B radiation (UVB, wavelengths 290 to 320 nanometers) is suspected to be 
associated with melanoma risk, because of the increased incidence in equatorial 
latitudes where UVB radiation is higher [83]. However, evidence suggests that 
ultraviolet A radiation (UVA, wavelengths 320 to 400 nanometers) is also associated 
with melanoma, shown by the association with the use of tanning beds [84, 85]. 
Reports about the association of psoralen ultraviolet A therapy (PUVA) with melanoma 
show a mild increase in melanoma incidence among patients exposed to PUVA 
compared to the general population [86, 87].
The only data that demonstrated a direct relation between UVA or UVB and melanoma 
are from animal experiments. These have shown that melanomas developed after 
neonatal exposure to UVB in transgenic mice [88-90]. Also, UVA exposure led to the 
development of melanomas in mice, but only when melanin pigment was present [91].
Between 21 and 42% of melanomas develop from pre-existing (dysplastic) nevi [92-94]. 
Dysplastic nevi are atypical melanocytic lesions that often share the same clinical 
features as melanomas, including one or more of the following: asymmetry, border 
irregularity, colour variability, or a diameter larger than 5 mm [95]. Melanomas that 
develop from nevi are often located on the trunk and have a weaker association with 
UV radiation. In contrast, most melanomas that occur ‘de novo’ are located on sun 
exposed areas and show a stronger association with UV radiation [96]. These observations 
are thought to present divergent pathways in the development of melanoma [96-98].
The increase in melanoma incidence in Western countries (and of skin cancer in 
general) can partly be explained by increased recreational sun bathing, sun holidays 
and lack of sun protection. However, it is only an assumption that recreational sun 
exposure has a causal role in the time trend in melanoma incidence. Some researchers 
therefore posed that we need to look beyond UV exposure in the aetiology of 
melanoma. Non-solar risk factors that have been studied include trauma, dietary 
factors, occupational exposures, viruses, drugs, hormonal factors, swimming water 
quality and obesity, all showing moderate - and possibly confounded - associations 
with melanoma risk [99-104].
Table 1 Genetic loci associated with (sporadic) melanoma risk
Authors Year Chromosome 
region
Reported 
gene(s)
SNP OR for 
 melanoma
Brown et al. [74] 2008 20q11 PIGU/CDC91L1 rs910873 1.75 
Gudbjartsson  
et al. [75]
2008 20q11
11q14
ASIP
TYR
rs1015362[G] 
rs4911414[T]
rs1126809
1.45
1.21
Falchi et al. [78] 2009 9p21
22q13
MTAP
PLA2G6
rs4636294
rs2284063
1.21
1.19
Bishop et al. [73] 2009 9p21
11q14
16q24
CDKN2A/MTAP
TYR
MC1R
rs7023329
rs1393350
rs258322
1.18
1.27
1.67
Duffy et al. [77] 2010 6p25 IRF4 rs12203592 1.15
Amos et al. [72] 2011 15q13
1q21.3
HERC2/OCA2
ANXA9
rs1129038
rs1722784
0.69
1.12
MacGregor  
et al. [82]
2011 1q21.3
1q42.12
ARNT, SETDB1
PARP1
rs7412746
rs3219090
0.89
0.90
Nan et al. [79] 2011 1q42 NID1 rs3768080[A]
rs10754833[T]
0.93
0.92
Barrett et al. [80] 2011 2q33
11q22
21q22
CASP8
ATM
MX2
rs13016963
rs1801516
rs45430
1.14
0.84
0.88
Iles et al. [81] 2013 16q12 FTO rs16953002 1.16
Zhang et al. [76] 2013 6p25
6p25
14q22
16q24
IRF4
IRF4 - EXOC2
GNG2
MC1R
rs12203592
rs12202284
rs8015138
rs1805007
1.23
1.16
1.12
1.40
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investigated by the pathologist. When melanoma cells are present, a total lymph-
adenectomy is advised (see also 1.4 Treatment) [111], although the benefit of this 
procedure in terms of overall or disease free survival is not yet confirmed [112]. 
There are four major subtypes of invasive melanoma: superficial spreading melanoma 
(SSM), which account for 60-70% of melanomas, nodular melanoma (NM, 15-30%), 
lentigo maligna melanoma (LMM, 10%) and acral lentiginous melanoma (ALM, 5%). 
Rare subtypes include amelanocytic melanoma, Spitzoid melanoma, desmoplastic 
melanoma, and malignant blue nevus [105]. Most subtypes harbour specific clinical 
and histopathological features.
Making the distinction between nevi and melanoma can be challenging, because 
some lesions harbour features of both. Especially differentiating lesions with Spitzoid 
histology can be problematic. A number of molecular techniques have become available 
which can facilitate this procedure, such as comparative genomic hybridization 
(CGH), fluorescence in situ hybridization (FISH) and RNA based gene expression 
panels [106]. These techniques can reveal specific point mutations or patterns of 
mutations which are specific for melanoma.
When a melanoma is diagnosed, Breslow thickness, the melanoma subtype, presence 
of ulceration, microsatellites, regression and the mitotic rate (the number of dermal 
mitosis per mm2) are reported. Ulceration, mitotic rate and microsatellites are prognostic 
factors. In case of regression, the Breslow thickness might not be accurate. Mitotic 
rate was recently incorporated in the 7th tumour-node-metastasis (TNM) staging 
classification of the American Joint Committee on Cancer (AJCC) and distinguishes 
between pathological tumour stage pT1a and pT1b (see Table 2) [107]. In the 
Netherlands, there is some discussion about the assessment of the number of 
mitoses. It is recommended to find a mitotic ‘hot spot’ and count mitoses in 1 mm2 , 
or to look for a single mitotic figure and look for more mitoses in the surrounding 
1 mm2. However, it is not stated how many slides should be assessed at the least, 
and often it is not clear if a single mitotic figure is situated in a melanocyte or another 
cell type. Finding a mitosis has clinical implications, as a sentinel node procedure is 
advised in patients with stage IB and higher (see section below) [108]. 
 Clark level of invasion was previously one of the standard items in the pathology 
report and part of TNM staging, but it was completely abandoned with the incorporation 
of mitotic rate. In addition, Clark level had a moderate interobserver agreement 
compared to the other characteristics [109].
In most melanoma cases, a sentinel node procedure can provide additional prognostic 
information and completes the TNM stage. In the latest Dutch guideline, it is advised 
that this procedure be offered to all melanoma patients with stage IB and higher (see 
Table 3) [110]. During this procedure, a fluid containing a radioactive tracer and dye 
is injected at the tumour site and the lymph nodes that are first reached by this fluid 
are traced. If technically feasible, these lymph nodes are surgically removed, and 
Table 2  TNM staging of melanoma
T Thickness (mm) Ulceration status/Mitoses
Tis NA NA
T1 ≤1.00 a: Without ulceration and mitosis <1/mm2
b: With ulceration or mitoses ≥ 1/mm2
T2 1.01-2.00 a: Without ulceration
b: With ulceration
T3 2.01-4.00 a: Without ulceration
b: With ulceration
T4 >4.00 a: Without ulceration
b: With ulceration
N No. of metastatic nodes Nodal metastatic burden
N0 0 NA
N1 1 a: Micrometastasis
b: Macrometastasis
N2 2-3 a: Micrometastasis
b: Macrometastasis
c:  In transit metastases/satellites without 
metastatic nodes
N3 4+ metastatic nodes, or matted 
nodes, or in transit metastases/
satellites with metastatic nodes
M Site Serum LDH
M0 No distant metastases NA
M1a Distant skin, subcutaneous, or 
nodal metastases
Normal
M1b Lung metastases Normal
M1c All other visceral metastases
Any distant metastasis
Normal
Elevated
Abbreviations: NA, not applicable; LDH, lactate dehydrogenase. Reprinted from “Final Version of 2009 
AJCC Melanoma Staging and Classification”, Balch et al., 2009, Journal of Clinical Oncology, vol. 27 no. 
36, 6199-6206. Copyright © 2009, American Society of Clinical Oncology.
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1.4  Treatment
The most important part of the initial treatment of non-metastasized melanoma is 
complete surgical removal of the primary lesion, achieved by both the diagnostic 
excision and a wide local (re-)excision of the lesion or the scar of the diagnostic 
excision. The Dutch melanoma guideline advises to apply re-excision margins based 
on the Breslow thickness: ranging from half a cm for in situ melanomas to two cm for 
melanomas with a Breslow thickness of two mm or more [115].
In case of a positive sentinel node, or if lymph node metastases are otherwise 
detected, a lymph node dissection of the affected nodal station is first choice therapy 
[111]. Studies have been performed on adjuvant treatments, such as interferon-α, but 
due to inconsistent study results, this is no standard treatment yet in the Netherlands 
[116].
For in transit or satellite metastases, surgery is one of the possibilities. When multiple 
lesions are present in one limb, isolated limb perfusion with melphalan with or without 
tumour necrosis factor (TNF) can be applied [116], though the value of this therapy is 
mainly palliative.
For advanced stage melanoma (i.e. with distant metastases), until recently only the 
chemotherapeutic dacarbazine was available, with a marginal effect on survival (i.e., 
a median survival of 6-9 months and 5-year survival rates of approximately 6%) [117]. 
Since 2011, a number of new therapies for stage IV melanoma have become available, 
which lengthen overall survival. First developed were inhibitors of the mitogen-acti-
vated protein (MAP) kinase pathway (BRAF and MEK inhibitors), and a CTLA4 
antibody, ipilimumab, which inhibits the downregulation of the T-cell response against 
cancer cells [118-120]. The stabilisation in the mortality rate in the last two years may 
be explained by the discovery of these new therapies.
 BRAF-mutations are present in about 50% of melanomas, and only patients that 
harbour a BRAF-mutant melanoma benefit from treatment with a BRAF-inhibitor, such 
as vemurafenib or dabrafenib. Response rates of over 50% occur and the median 
progression free survival (PFS) is reported to be 7 months [118, 119]. Drug toxicities 
thought to be caused by paradoxical activation of the MAPK pathway [121-123] 
include hyperkeratosis, cutaneous squamous cell carcinoma (SCC) and alopecia. 
With vemurafenib, the incidence of SCCs during treatment ranges from 4-30% [118, 
124] and with dabrafenib, from 6-11% within a couple of months [119, 124]. Arthralgia 
and photosensitivity are also reported with vemurafenib, and fever with dabrafenib. 
Usually side effects are mild and do not require drug discontinuation. However, 
resistance against BRAF-inhibition can still not be prevented and complete, long 
In 2-3% of cases, melanoma patients present with a melanoma metastasis but 
without a primary melanoma, an entity called melanoma of unknown primary origin 
(MUP) [113, 114]. Because a primary tumour is absent (or not found), TNM staging of 
MUP is not as straightforward as in melanoma of known primary (MKP). The T stage 
cannot be determined and in case of nodal metastases, it is impossible to determine 
whether these are regional or distant. This creates a challenge for practitioners when 
deciding on the treatment that should be offered and informing patients about their 
prognosis.
Table 3  Anatomic stage groupings for cutaneous melanoma
Clinical staging Pathological staging
T N M T N M
0 Tis N0 M0 0 Tis N0 M0
IA T1a N0 M0 IA T1a N0 M0
IB T1b
T2a
N0
N0
M0
M0
IB T1b
T2a
N0
N0
M0
M0
IIA T2b
T3a
N0
N0
M0
M0
IIA T2b
T3a
N0
N0
M0
M0
IIB T3b
T4a
N0
N0
M0
M0
IIB T3b
T4a
N0
N0
M0
M0
IIC T4b N0 M0 IIC T4b N0 M0
III Any T N>N0 M0 IIIA T1-4a
T1-4a
N1a
N2a
M0
M0
IIIB T1-4b
T1-4b
T1-4a
T1-4a
T1-4a
N1a
N2a
N1b
N2b
N2c
M0
M0
M0
M0
M0
IIIC T1-4b
T1-4b
T1-4b
Any T
N1b
N2b
N2c
N3
M0
M0
M0
M0
IV Any T Any N M1 IV Any T Any N M1
Reprinted from “Final Version of 2009 AJCC Melanoma Staging and Classification”, Balch et al., 2009, 
Journal of Clinical Oncology, vol. 27 no. 36, 6199-6206. Copyright © 2009, American Society of Clinical 
Oncology.
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(4) To investigate the effect of the addition of mitotic rate to the staging protocol on 
the pathological tumour (pT) substaging of thin (pT1) cutaneous melanomas and 
the possible clinical implications (Chapter 5).
(5) To assess the frequency of residual tumour cells in re-excision specimens of 
completely excised cutaneous melanomas and the possible relation with the 
number of investigated blocks. With this knowledge we will evaluate the current 
guideline on the handling of re-excision specimens, which now advises to review 
only one central block. Since residual tumour cells are only rarely present the 
examination of re-excision specimens may be omitted (Chapter 6).
A general discussion on these matters and future perspectives for melanoma 
research are included in Chapter 7 of this thesis.
Most studies were performed within a framework of a genome-wide association 
study (GWAS) aiming to find new melanoma susceptibility genes. Patients included 
in this study were all recruited via the Netherlands Cancer Registry (NCR). In the NCR 
all newly diagnosed cancers in the Netherlands are recorded since 1989. The NCR 
has nationwide coverage and its completeness is estimated over 95% [139]. Clinical 
data were derived from the NCR and in addition, data were collected from medical 
files, and through questionnaires on general health, lifestyle and melanoma risk 
factors. In order to verify all melanoma diagnoses, a pathology review of primary 
melanomas was performed by an expert dermatopathologist.
term remission of the metastasized melanoma is achieved in virtually none of the 
cases [125, 126].
 MEK inhibitors, such as trametinib, have been proven effective in patients with 
V600 BRAF-mutant melanoma who are MAPK-inhibitor naïve, though response rates 
and PFS are lower than with BRAF inhibitors [127-129].
 Ipilimumab has been shown to be effective in about 11-15% of patients, with a 
late-onset and often long term effect [120, 130]. It is still difficult to predict which 
patients will benefit, and immune related toxicities include inflammatory cutaneous, 
gastrointestinal and endocrine conditions. Recently, a study comparing ipilimumab 
with dacarbazine versus placebo with dacarbazine found an overall median survival 
of 11.2 versus 9.1 months [131]. 
 More recently, other immune checkpoint blocking agents were developed, 
including PD-1 and PD-L1 antibodies, which prevent T cell inactivation at the tumour 
level, showing promising results [132-135]. Also, BRAF and MEK inhibitors are now 
being used in combination, and have been shown to improve treatment duration and 
reduce toxicity [136-138].
1.5  Aims and outline of this thesis
The main objective of this thesis was to increase knowledge on some epidemiological 
and clinical aspects concerning cutaneous melanoma that were not or insufficiently 
studied in the past, and are relevant for daily clinical practice. More specifically, the 
aims of this thesis were:
 
(1) To give insight in the characteristics and survival of different subgroups of 
patients with melanoma of unknown primary origin (MUP) and make comparisons 
with patients with melanoma of a known primary origin (MKP). With this knowledge, 
practitioners can offer adequate treatment to patients with MUP and better inform 
them about their prognosis (Chapter 2).
(2) To investigate the reproducibility of a self-reported questionnaire on sun exposure 
and other melanoma risk factors. Questionnaires are frequently used to measure 
risk factors in melanoma research, and it is important to know their precision 
(Chapter 3).
(3) To identify risk factors for developing a second primary melanoma. Melanoma 
patients are at increased risk for developing second melanomas and no consistent 
set of prognostic factors has been identified yet. The results of this study can 
help clinicians identify patients at higher risk of second primary melanoma and 
develop targeted follow-up schedules (Chapter 4).
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Abstract 
Background
Few population-based studies have been published on melanoma of unknown 
primary origin (MUP). This study’s aim is to describe characteristics and survival of 
MUP patients in the Netherlands, based on nationwide data from the Netherlands 
Cancer Registry (NCR).
Methods
Patient and tumour characteristics of MUP patients were retrieved from the NCR. 
Subgroups were made according to metastatic site: nodal or distant. Survival rates 
were calculated using the Kaplan–Meier method. To obtain a better insight in the 
composition and prognosis of the MUP group, the survival was compared to that of 
patients with melanoma of a known primary origin (MKP), tumour-node-metastasis 
(TNM) stage III and IV.
Results 
Of all 33,181 melanoma patients diagnosed between 2003 and 2009, 2.6% (n = 857) 
were diagnosed with MUP. MUP patients with nodal metastases had a similar survival 
as MKP stage III with macroscopic nodal involvement. After stratification according to 
the number of involved lymph nodes, the survival of patients with nodal metastases 
with one involved lymph node was not significantly different between MUP and MKP. 
The survival of MUP patients with two or more involved lymph nodes was slightly 
worse than that of MKP stage III patients with macroscopic nodal involvement with 
two or more involved lymph nodes. MUP patients with distant metastases had a 
similar survival as MKP stage IV. After stratification according to number of metastatic 
sites and metastatic site category, the survival in MKP stage IV patients with (sub)
cutaneous metastases was slightly worse than MUP distant patients with (sub)
cutaneous metastases.
Conclusions
The results of this study imply that MUP patients form a heterogeneous group, and 
that MUP patients with nodal metastases could be classified as stage III melanoma 
with macroscopic nodal involvement, and MUP patients with distant metastases as 
stage IV melanoma.
Introduction
Melanoma is usually discovered as a skin lesion. However, about 2-3% of all melanoma 
patients present themselves with a melanoma metastasis without a detectable primary 
tumour [1-3]. This is referred to as melanoma of unknown primary origin (MUP). 
Several theories have been proposed for the aetiology of MUP, including the following: 
a MUP may arise from (i) a melanoma that was excised and misdiagnosed or not 
further investigated histopathologically; (ii) a regressed melanoma; or (iii) malignant 
transformation of a nevus cell in a lymph node or other non-skin tissue. In support of 
the last two theories, partial spontaneous regression of melanomas occurs frequently 
and may be due to immunological mechanisms [4, 5]. Benign nevus cells are 
commonly found in lymph nodes and other tissues, and melanomas arising from 
nevus cells in lymph nodes have been described [6, 7].
MUP patients comprise a heterogeneous group. Like patients with metastatic melanoma 
of a known primary (MKP), MUP patients can present with (sub)cutaneous, nodal 
metastasis and/or metastasis to the viscera, bones or brain. In patients with only 
(sub)cutaneous or nodal metastases it is impossible to differentiate between regional 
versus distant metastases, as the primary site is unknown. This distinction would be 
important for assessment of prognosis.
Most of what is known about the prognosis of MUP patients is derived from hospital- 
based studies. Based on these studies, MUP patients with nodal metastases seem 
to have a similar [8-10] to better [11-13] survival than MKP patients with nodal 
metastases. MUP patients with distant metastases seem to have a survival similar or 
even better compared with MKP patients with distant metastases [1, 14, 15].
Population-based studies on this subject are scarce. In 1998, Chang et al. reported 
on 84,836 melanoma cases diagnosed between 1985 and 1994 from the American 
National Cancer Data Base, of which 2.2% had an unknown primary [1]. To our 
knowledge, no recent population-based study on MUP has been published since. 
This type of study can provide interesting, unselected information on this patient 
group. Therefore, the aim of this study is to describe characteristics and survival of 
the different subgroups of MUP patients, based on unselected, population-based 
data retrieved from the Netherlands Cancer Registry (NCR) database. To give insight 
in the composition and prognosis of this heterogeneous patient group, survival 
analyses were performed and stratified comparisons with stage III and IV MKP 
patients were made. 
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Patients and methods
Patients
This population-based study was based on all melanoma patients diagnosed in the 
Netherlands between 1st January 2003 and 31th December 2009. In the NCR, held by the 
Comprehensive Cancer Centre the Netherlands, all newly diagnosed malignancies are 
recorded. It has nationwide coverage since 1989. Patient and tumour characteristics, 
primary treatment and vital status are recorded in the NCR. Vital status of all patients 
registered in the NCR is updated annually by record linkage to the Dutch Municipal 
Personal Records Database, which keeps information about vital status of all inhabitants 
in the Netherlands. For patients diagnosed with metastatic cancer, the NCR records 
the location of metastases using the International Classification of Diseases-Oncology 
(ICD-O) classification.
Patients diagnosed with melanoma were identified by the morphology codes 8720-8780 
(ICD-O-3). Based on the topography code, these patients were classified as MUP 
patients (topography C80) or MKP patients (all topography codes except C80). 
Patients with a C80 topography but with a prior history of primary melanoma were 
excluded from the analyses. Because cutaneous and non-cutaneous melanomas 
comprise separate entities with different TNM staging classifications, only MKP 
patients with a cutaneous melanoma (topography C44) were included in this study. 
All non-cutaneous primary melanoma localisations were excluded. Since the Union for 
International Cancer Control (UICC) TNM staging protocol for cutaneous melanoma 
changed markedly in the transition from the fifth to the sixth edition, only cases 
diagnosed after the implementation of the sixth edition were included (1st January 
2003)[16-18]. For each patient, age at diagnosis, gender, clinical and post-surgical 
TNM stage, number of involved lymph nodes, location of metastases present at 
diagnosis, primary treatment, and vital status were retrieved from the NCR.
Two MUP subgroups were made based on the localisation of their metastases. 
Subgroups were made based on the most stage-defining metastasis: (i) only nodal 
metastases and (ii) any (sub)cutaneous, visceral, bone or brain metastasis, hereafter 
called MUP nodal and MUP distant respectively. Patients with cutaneous or sub - 
cutaneous metastases were categorised as ‘distant’, because most patients with 
subcutaneous metastases likely have distant metastases. Patients with cutaneous 
metastases could in fact have in transit or satellite metastases and therefore could 
have a better prognosis. Unfortunately a distinction between locoregional and distant 
skin metastases cannot be made, since the primary tumour is unknown. We therefore 
chose this classification, and analysed patients with (sub)cutaneous separately in the 
stratified analysis. In 142 MUP patients (17%) information on the metastatic site was 
missing. These patients were excluded from the subgroup analyses. MKP patients 
were divided into TNM stage III and IV. MUP nodal patients most likely have 
macroscopic clinically palpable metastases, and MKP stage III also includes patients 
with microscopic nodal metastases and in transit or satellite metastases. Therefore, 
MKP stage III was further subdivided into patients with microscopic nodal involvement, 
macroscopic nodal involvement, and in transit or satellites metastases. 
For further comparisons with the MUP nodal group, only MKP stage III patients with 
macroscopic metastases were taken into account, hereafter called MKP stage III 
macroscopic. For the MUP nodal and the MKP stage III macroscopic group, the 
number of involved lymph nodes was recorded as zero, one, or two or more. This 
classification was based on available information on the number of lymph nodes 
from the NCR. The number of distant metastatic sites (one, or two or more) and three 
major metastatic site categories ((sub)cutaneous or lymph nodes beyond regional 
lymph nodes, lung, and other sites) were recorded for the MUP distant and MKP 
stage IV subgroups.
Statistical methods
The percentage of MUP relative to all melanoma cases diagnosed between 2003 and 
2009 was determined. Crude (i.e. all cause) survival was calculated using the 
Kaplan-Meier method. Follow-up time was calculated and defined as the time 
between date of diagnosis and date of death, date of emigration or end of follow-up 
(1st January 2010), whichever came first. Two- and five-year survival estimates with 
95% confidence intervals (95% CI), and median survival time (months) were estimated 
for the two MUP subgroups and MKP stage III and IV. In MUP nodal and MKP stage 
III macroscopic patients, the survival estimates were calculated for one versus two or 
more involved lymph nodes, and in the MUP distant and MKP stage IV patients, for 
one versus two or more metastatic sites, and for the metastatic site categories 
separately. Differences in the short term (5-year) survival were tested with the Breslow 
(Generalised Wilcoxon) test. A p-value of 0.05 was considered statistically significant.
In order to evaluate the comparability of the prognosis of the different MUP subgroups 
with the prognosis of the MKP stage groups , the survival of MUP patients with nodal 
metastases was compared with the survival of MKP stage III macroscopic patients, 
and the survival of MUP patients with distant metastasis was compared to that of 
MKP stage IV patients. In addition, for the MUP nodal and MKP stage III macroscopic 
group, stratified comparisons were made according to the number of involved lymph 
nodes. This was also done for the MUP distant and MKP stage IV group, according 
to the number of metastatic sites, and according to metastatic site category. Gender 
specific survival was calculated and compared for all MUP and MKP subgroups.
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The statistical analyses were performed with SPSS 18.0 software (SPSS Inc., Chicago, IL). 
The data retrieval was approved by the Institutional Review Board (IRB) of the 
Netherlands Cancer Registry.
Results 
Overall, 33,181 patients were diagnosed with melanoma between 2003 and 2009. Of 
all melanoma patients, 2.6% (n = 857) were diagnosed with a melanoma of unknown 
primary origin.
In Table 1 patient and tumour characteristics of MUP patients by subgroup and cutaneous 
MKP stage III and IV patients are presented. Of the MUP patients, 28% (n = 237) had 
only nodal metastases and 56% (n = 478) had distant metastasis. For 17% (n = 142) 
the metastatic site was unknown. The male:female ratio was not significantly different 
between the subgroups of MUP and MKP patients, as was median age. The proportion 
of patients that was treated with a lymph node dissection was not significantly 
different between MUP nodal and MKP stage III macroscopic patients (60% versus 
61%, p = 0.935), nor was the proportion of patients that received radiotherapy (20% 
versus 16%, p = 0.169) or systemic therapy (29% versus 27%, p = 0.635) between 
MUP distant and MKP stage IV.
Survival curves of the MUP nodal and distant subgroups are presented in Fig.1. 
The survival of the nodal subgroup was significantly different from that of the distant 
subgroup ( p < 0.001). 
Fig. 2A shows a significantly worse survival of the MUP nodal subgroup compared 
with MKP stage III (p = 0.001), though a similar survival of the MUP nodal subgroup 
compared to MKP stage III macroscopic (p = 0.374). Furthermore, Fig. 2B shows a 
similar survival of the MUP distant subgroup compared with MKP stage IV (p = 0.486). 
In Fig. 3A and B, stratified comparisons are shown for the survival of the MUP nodal 
and MKP stage III macroscopic subgroup, according to the number of involved 
lymph nodes. MUP nodal patients with one involved lymph node had a similar survival 
as MKP stage III macroscopic patients with one involved lymph node (p = 0.632). 
However, MUP nodal patients with two or more lymph nodes involved had a worse 
survival than MKP stage III macroscopic patients with two or more involved lymph 
nodes (p < 0.001). Fig. 4A and B show stratified comparisons for the survival of the 
MUP distant and MKP stage IV subgroup, according to the number of metastatic 
sites. MUP distant patients and MKP stage IV patients with one metastatic site had a 
similar survival (p = 0.211). MUP distant patients with two or more metastatic sites 
Table 1  Patient and metastasis characteristics of patients with a melanoma of unknown 
primary origin, for patients with nodal and distant metastases, and of patients with a melanoma 
of known primary origin, stage III and IV, according to the UICC TNM classification, 6th edition.
MUP (n = 857) MKP (n = 1,975)
Subcategory Nodal
n (%)
Distanta
n (%)
Stage III
n (%)
Stage IV
n (%)
Total no. b 237 (27.7) 478 (55.8) 1,689 (85.5) 286 (14.5)
Gender
- Male
- Female
138 (58.2)
99 (41.8)
270 (56.5)
208 (43.5)
931 (55.1)
758 (44.9)
166 (58.0)
120 (42.0)
Age at diagnosis, median (range) 61 (15-92) 61 (7-97) 57 (8-99) 61 (18-97)
Stage III substage
- Microscopic nodal 
- Macroscopic nodal
- In transit or satellite
NA NA 783 (46.4)
625 (37.0)
281 (16.6)
NA
Primary treatment
- Lymph node dissection c
- Systemic therapy
- Radiotherapy
143 (60.3)
138 (28.9)
96 (20.1)
379 (60.6)
78 (27.3)
46 (16.1)
Number of nodal metastases
0
1
≥2
Unknown 
214 (90.3)
 23 (9.7)
 NA 61 (3.6)
806 (47.7)
540 (32.0)
282 (16.7)
NA
Number of distant metastatic sites
1
≥2
Unknown 
NA 244 (51.0)
234 (49.0)
NA 107 (37.4)
127 (44.4)
52 (18.2)
Site of distant metastases
-  (Sub)cutaneous or LN  
beyond regional LN d
- Lung
- Other sites 
- Unknown
NA 106 (12.4)
41 (4.7)
331 (38.7)
NA 47 (16.4)
43 (15)
144 (81.8)
52 (18.2)
Abbreviations: MUP, melanoma of unknown primary origin; MKP, melanoma of known primary origin; 
NA, not available; LN lymph node.
a  MUP distant includes patients with any (sub)cutaneous, visceral, bone or brain metastasis.
b  For 142 MUP patients (16.6%), the metastatic site was unknown or missing.
c  In the MKP patients, the number of lymph node dissections is reported for MKP stage III patients with 
macroscopic nodal involvement.
d  In MUP patients, this includes only patients with (sub)cutaneous metastases, since patients with nodal 
metastases were categorised into a separate group.
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had a slightly worse survival than MKP stage IV patients with two or more metastatic 
sites (p = 0.008). Fig. 5A, B and C show stratified comparisons for the survival of the 
MUP distant and MKP stage IV group, according to metastatic site category. MUP 
distant patients with (sub)cutaneous metastases had a better survival than MKP stage IV 
patients with (sub)cutaneous or distant lymph nodes (p = 0.036). MUP distant and 
MKP stage IV patients with lung metastases had a similar survival (p = 0.800), as well 
as patients with other distant metastases (p = 0.233).
In Table 2, 2- and 5-year survival estimates with 95% confidence intervals and median 
survival time (months) are presented for all the subgroups previously mentioned.
Gender specific survival analyses showed no significant differences between males 
and females in the MUP subgroups or the MKP stage III and IV groups. 
Figure 1  Crude survival probabilities according to Kaplan-Meier analysis for patients with a 
melanoma of unknown primary, by metastatic site category.
Figure 2  Crude survival probabilities according to Kaplan-Meier analysis of (A) patients with 
melanoma of unknown primary origin nodal metastasis versus patients with a melanoma of 
known primary origin, stage III, and stage III with macroscopic nodal metastases, according to 
the UICC TNM classification, 6th edition, and (B) of patients with melanoma of unknown primary 
origin with distant metastases versus patients with a melanoma of known primary, stage IV, 
according to the UICC TNM classification, 6th edition.
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Figure 3  Crude survival probabilities according to Kaplan-Meier analysis of patients with a 
melanoma of unknown primary origin and nodal metastases, and patients with a melanoma of 
known primary origin, stage III with macroscopic nodal metastases, according to the UICC TNM 
classification, 6th edition, for (A) patients with only one involved lymph node and (B) patients 
with two or more involved lymph nodes.
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Figure 4  Crude survival probabilities according to Kaplan-Meier analysis of patients with a 
melanoma of unknown primary origin and distant metastases, and patients with a melanoma 
of known primary origin, stage IV according to the UICC TNM classification, 6th edition, for (A) 
patients with only one metastatic site and (B) patients with two or more metastatic sites.
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Figure 5  Crude survival probabilities according to Kaplan-Meier analysis of patients with a 
melanoma of unknown primary origin and distant metastases, and patients with a melanoma 
of known primary origin, stage IV according to the UICC TNM classification, 6th edition, for (A) 
patients with (sub)cutaneous metastases or, for patients with a melanoma of known primary, lymph 
node metastases, (B) patients with lung metastases and (C) patients with other metastatic sites.
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Discussion
Of all the melanomas diagnosed between 2003 and 2009, 2.6% had a melanoma of 
unknown primary origin, which is comparable to the percentage found in other 
studies [1, 2, 8, 10].
When comparing the survival of MUP patients with nodal metastases to that of MKP 
stage III, we found that the latter fared slightly though significantly better. However, 
when we only took MKP stage III patients with macroscopic nodal involvement into 
account, the survival was not significantly different. This can be explained by the fact 
that most MUP nodal patients probably present with macroscopic disease. After 
stratification according to the number of involved lymph nodes, the survival was 
worse in the MUP nodal subgroup with two or more involved lymph nodes. This may 
be explained by the fact that in the MUP nodal subgroup, patients with regional 
metastases are probably intermixed with patients with metastases to distant nodal 
basins. Most likely, patients with two or more lymph nodes involved belong in this 
latter category.
It can be assumed that MUP nodal patients have a similar survival as stage III patients 
with macroscopic nodal involvement, and therefore could be regarded as TNM stage 
III patients with macroscopic involvement. However, when MUP patients have two or 
more lymph nodes involved, their prognosis may be worse. Since this stratified 
analysis was based on only 25 patients in the MUP nodal subgroup, conclusions 
should be drawn carefully. 
Other studies reported a similar to better survival for MUP nodal patients [8-12, 15, 19, 
20], and Pfeil et al. recently posed that MUP patients with lymph node metastases 
can be staged as AJCC stage III [3]. However, based on our results, we conclude that 
MUP nodal patients can only be compared with MKP stage III patients with 
macroscopic nodal involvement. Furthermore, the MUP nodal group theoretically 
also includes patients with distant nodal metastases.
In this study, MUP distant patients appear to have a similar survival as MKP stage IV 
patients. When making stratified comparisons, the survival was not significantly 
different in patients with one metastatic site and patients with lung or other metastatic 
sites. Only in the patients with (sub)cutaneous metastases the survival was 
significantly better for MUP patients. An explanation might be that MUP patients with 
(sub)cutaneous metastases could also have in transit or satellite metastases, with a 
better prognosis. In patients with two or more metastatic sites, the survival was 
significantly worse for MUP patients. This survival difference, however, was small. We 
Table 2  Two- and five-year survival percentages and median survival time in months, for 
patients with melanoma of unknown primary origin and patients with a cutaneous melanoma 
of known primary origin.
n Two-year 
 survival
Five-year 
 survival
Median  
survival time 
% (95% CI) % (95% CI) Months
MUP
Nodal, all 327 64.6 (57.9-71.4) 52.0 (43.9-60.0) NA
- Nodal, 1 LN involved
- Nodal, ≥ 2 LN involved
214 
23
68.8 (61.9-75.8)
22.7 (2.3-43.1)
56.0 (47.6-64.4)
15.1 (0-33.3)
NA
8.9
Distant, all 478 23.9 (19.7-28.2) 14.0 (8.7-19.3) 6.7
- Distant, 1 metastatic site
- Distant, ≥ 2 metastatic sites
244 
234 
42.6 (35.7-49.6)
4.2  (1.2-7.2)
25.5 (16.1-34.8)
0
16.8
3.2
- Distant, (sub)cutaneous
- Distant, lung
- Distant, other sites
106
41
331
62.2 (51.6-72.9)
36.6 (20.4-52.1)
10.0 (6.2-13.7)
35.3 (18.5-52.0)
14.7 (0-30.7)
7.7 (3.7-11.7)
54.7
12.5
3.2
MKP
Stage III, all 1,689 75.8 (73.5-78.1) 54.6 (51.3-57.9) NA
- Stage III, macro, all
-  Stage III, macro,  
1 LN involved
-  Stage III, macro,  
≥ 2 LN involved
625
271
306 
52.0 (48.2-55.8)
67.9 (62.1-73.6)
46.7 (41.0-52.4)
35.0 (30.7-39.3)
50.1 (43.0-57.3)
27.1 (20.7-33.5)
25.6
NA
21.4
Stage IV, all 286 20.1 (15.0-25.1) 8.9 (4.5-13.3) 6.3
- Stage IV, 1 metastatic site
-  Stage IV,  
≥ 2 metastatic sites
107 
127 
33.6 (23.7-43-4)
6.8 (1.7-11.8)
14.5 (4.8-24.3)
4.1 (0-8.3)
11.9
4.4
-  Stage IV, subcutaneous or 
LN beyond regional LN
- Stage IV, lung
- Stage IV, other sites
47
43 
144
44.9 (28.5-61.3)
34.7 (19.6-49.7)
5.5 (0-9.9)
35.3 (17.5-53.0)
5.4 (0-15.3)
1.5 (1.2-4.1)
17.3
12.4
4.4
Abbreviations: MUP, melanoma of unknown primary origin; MKP, melanoma of known primary origin; 
NA, not available; LN lymph node; macro, macroscopic nodal involvement.
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conclude therefore that MUP distant patients could be staged as TNM stage IV. 
Only a few other recent studies reported on MUP patients with distant metastases, 
and some showed a similar survival to MKP stage IV patients [3, 10], including the 
population- based report by Chang et al., which reported a 5-year survival of 16% 
compared with 18% in the stage IV MKP group [1].
Only one study by Lee et al. made detailed comparisons between the survival of 
stage IV categories M1a, M1b and M1c of MUP and MKP patients, and they found a 
better survival for the MUP stage IV M1b and M1c group (i.e. metastases to the lungs 
or other viscera) compared with MKP [14]. We could not replicate this survival benefit 
for the MUP distant group over the MKP stage IV group with lung or other metastases.
It is argued by several researchers that MUP patients have a better prognosis than 
MKP patients due to the same immunological mechanisms responsible for the 
regression of the primary tumour [12, 13, 15]. The literature on the survival of MUP 
patients versus MKP patients however, is not consistent. Moreover, Guiliano et al. 
were unable to identify differences in cellular immune responses between patients 
with a known or unknown primary melanoma [4].
When comparing the absolute survival estimates of the different MUP subgroups (i.e. 
nodal and distant) to those found by other studies, the absolute 5-year survival for 
MUP patients with nodal metastases (52%) was similar to that found in other study 
populations (46-55%) [10-12]. In some studies it was worse than in the present study 
(39-41%) [2, 9, 13] and in some studies a better survival was reported (57-60%)[3, 19, 20].
For MUP patients with distant metastases, most studies found a better survival than 
in the present study [3, 14, 20]. These studies were hospital-based, thereby possibly 
selecting patients from a certain region or income group or even prognosis. Some 
only included melanoma patients with resected nodal metastases, possibly selecting 
a healthier group with a survival benefit over other, unselected patient groups. In the 
population-based study from the United States by Chang and colleagues, the 5-year 
survival of MUP patients with nodal metastasis was slightly lower (46% versus 52% in 
our cohort), though that of MUP patients with distant metastases was better (16% 
versus 14% in our cohort) [1]. This study was performed in the United States, so the 
population under study may have had a different ethnic and socio-economical 
composition than the Dutch population.
In this study we were able to use data of all Dutch melanoma patients diagnosed 
from 2003 to 2009. This gave us the opportunity to identify the actual proportion 
of MUP relative to all melanoma diagnoses and review a large, unselected group of 
MUP patients. Furthermore, we had information on the localisation of metastases in 
most MUP patients, making stratified analyses possible. To the best of our knowledge, 
this is only the second population-based study that describes the characteristics and 
survival of MUP.
As the data was derived from the NCR, only information recorded in the NCR could 
be included in this study. Prognostic factors such as tumour ulceration, micro- or 
macrometastasis, or elevated LDH were not available, or only available for MKP and 
not for MUP patients. Information on the primary treatment was available, and we 
found no significant differences between the MUP and MKP group. We decided to 
perform stratified comparisons for the number of nodes and metastatic sites, and 
metastatic site categories, to give a descriptive analysis of the composition and 
survival of the MUP group. A Cox regression model including more prognostic factors 
would make it possible to explain survival differences better, but unfortunately the 
data was limited.
In conclusion, the results of this study imply that MUP patients represent a hetero -
geneous group, that MUP patients with nodal metastases have a similar survival 
compared with MKP stage III patients with macroscopic involvement, and that MUP 
patients with distant metastases have a similar survival as MKP stage IV patients. The 
problem remains that physicians cannot distinguish which of their MUP patients have 
a regional or a distant (sub)cutaneous or nodal metastasis. They should mention this 
fact when informing these patients about their prognosis and should take this into 
account when classifying them into the existing TNM staging categories.
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Abstract
Background
As melanoma researchers continue to investigate environmental and lifestyle-related 
risk factors, questionnaire data remain important. The reproducibility of a questionnaire 
on melanoma risk factors was investigated using a test-retest approach in 389 Dutch 
melanoma patients.
Methods
In 2011, 389 melanoma patients filled out a questionnaire on melanoma risk factors 
twice. Test-retest reproducibility was assessed by calculating kappas (κ), weighted 
kappas (κw) and intraclass correlation coefficients (ICCs) for categorical, ordinal and 
continuous variables, respectively. Stratified analyses were carried out by gender, 
age group, education level, and time since diagnosis.
Results
The median time between the questionnaires was 31 days. The reproducibility was 
substantial for questions regarding phenotypic characteristics (κ/κw/ICC=0.62-0.77), 
fair-to-substantial for sun exposure and sun protection behaviour (κ/κw/ICC=0.38-
0.79), and moderate for sunburn history (κ/κw=0.42-0.51). No clear differences were 
observed between men and women. Younger patients showed a better reproducibility 
in nine of the 29 questions compared with older patients and higher educated patients 
showed a better reproducibility in four of the 29 questions. Patients with a diagnosis 
shorter than 1.5 years ago had a better reproducibility in four out of 29 items compared 
with patients with a diagnosis 1.5-3.0 years ago.
Conclusions
Our study showed that self-reported information on melanoma risk factors is fairly 
well reproducible. Although this does not guarantee validity, this type of questionnaire 
seems to be useful in research settings. The reproducibility is slightly better in young 
patients and patients with a higher education level, which can be taken into account 
when interpreting results from epidemiological studies.
Introduction
Cutaneous melanoma is among the most aggressive types of skin cancer and its 
incidence is increasing worldwide [1, 2]. Intermittent exposure to ultraviolet radiation 
and a history of sunburns are established lifestyle-related risk factors for CM [3]. The 
most commonly used method to measure these risk factors is through self-reports, 
that is questionnaires and interviews.
The quality of a questionnaire or interview has two aspects: i) validity or accuracy, 
and ii) precision or reproducibility. The validity of questions on phenotypic traits can 
be assessed by comparing self-reported scores to a ‘gold standard’ measure, e.g., 
the assessment of skin colour or nevus counts by a trained nurse or physician. For 
questions on sun behaviour or sun burn history, this is virtually impossible. The 
precision of the questionnaire items can be measured by the test-retest reproducibility 
of the provided answers. The reproducibility coefficient can be used to correct effect 
measures (e.g. odds ratios) for bias due to imprecise measurements if certain 
assumptions are met [4].
A number of studies assessed the test-retest reproducibility for questionnaires 
investigating melanoma risk factors, but only a few of these included melanoma 
patients. These studies found a wide range in reproducibility (poor-to-good), depending 
on the type of question [5-8]. Questions on phenotypic characteristics tend to have a 
higher reproducibility than questions concerning sun exposure history [5].
Melanoma patients may report their sun exposure history differently than other patients 
with nonmelanoma skin cancer or healthy individuals because of their knowledge of 
the hazardous nature of UV-radiation. Also, patients may confuse sun exposure and 
sun protection behaviour before and after the diagnosis of melanoma.
To increase the knowledge on the reproducibility of melanoma risk factor questionnaires 
in melanoma patients, we investigated the reproducibility of a detailed postal 
questionnaire in 389 Dutch melanoma patients. This population size allowed us to 
carry out subgroup analyses by patient characteristics such as age, sex, education 
level and time since diagnosis.
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Methods
Patients
The present study was part of an ongoing population-based study on the association 
of genetic variants and lifestyle-related factors with the risk and prognosis of 
melanoma. In total, 1,808 Dutch melanoma patients were selected and invited for this 
study through the Netherlands Cancer Registry (NCR). All patients were diagnosed 
with a melanoma in the period 2003-2011 and invitations were sent in two batches, 
one in May 2008 including patients diagnosed between 2003-2008 (n=1165) and 
one in April 2011 (n=643) including patients diagnosed between 2009-2011. The 
second group of patients was invited in 2011 in order to obtain sufficient statistical 
power in the genetic association study. Participation in this study included donating a 
blood sample and completing a questionnaire on general health items and melanoma 
risk factors. Ethical approval was given by the local Medical Ethics Committee. 
The current reproducibility study focused only on the 643 patients who were invited 
in April 2011. All patients were asked to fill out the first questionnaire as mentioned 
above and a second questionnaire containing a selection of the questions of the first 
questionnaire, mailed at least two weeks after receiving the first questionnaire. 
Patients recruited in 2008 were not included in the reproducibility study because time 
between the first and second questionnaires was too long (i.e., at least 3 years).
Questionnaires
The first questionnaire (Q1) was divided into nine parts, covering the following: a) 
country of birth of the patient and the patient’s parents and grandparents, race, sex, 
marital status, b) height and weight, c) education and profession, d) smoking history, 
e) alcohol use, f) physical activity, g) specific risk factors for melanoma (i.e. phenotypic 
characteristics such as skin, eye, and hair colour, sun exposure and sun protection 
behaviour during childhood and adulthood), h) general health (i.e. presence of 
co-morbidities and medicine use), and i) family history of cancer.
From part g, covering melanoma risk factors, a selection of 29 questionnaire items 
was included in the second questionnaire (Q2), which covered three categories: 
‘phenotypic characteristics’, ‘sun exposure and sun protection behaviour’ and 
‘sunburn history’. Sunburn history was considered a separate category because it 
was reported to be an independent risk factor for melanoma. See Table 1 for the 
questions included in Q2, including the answer categories. 
Analyses
Descriptive analyses were carried out for the respondents to both Q1 and Q2. For the 
questions that were identical in Q1 and Q2, the reproducibility was assessed by 
computing kappa (κ) for dichotomous items, weighted kappa (κw) with Cicchetti- 
Allison weights for ordinal items, and intraclass correlation coefficients (ICCs) for 
continuous items. The strength of the κ or ICCs was interpreted as suggested by 
Landis and Koch [9], that is, poor if κ≤0.20, fair if 0.20<κ≤0.40, moderate if 
0.40<κ≤0.60, substantial if 0.60<κ≤0.80 and good if κ>0.80. For every item category 
(i.e., ‘phenotypic characteristics’, ‘sun exposure and sun protection behaviour’ and 
‘sunburn history’) a median κ or ICC and a range was calculated.
Subgroups were defined on the basis of sex, age at time of completing Q1 (<40, 
40-70, >70 years), education level (primary school or secondary school graduate, 
versus postsecondary education graduate or higher) and the time between date of 
diagnosis and date of completing Q1 (<1.5 years, 1.5-3.0 years and >3.0 years). The 
reproducibility coefficients for the 29 questionnaire items were calculated for all 
patients and for every subgroup. Between subgroups, comparisons were made for 
every separate item. We considered differences in the reproducibility of more than 
0.20, the category width in the Landis and Koch classification, in kappa or ICC 
between subgroups relevant. Differences were tested by a Fisher Z transformation 
and a p-value < 0.05 was considered statistically significant.
The statistical analyses were carried out using the SPSS 20.0 software (IBM Corp., 
Chicago, USA) and SAS 9.2 (SAS Institute Inc., Cary, USA).
Results
Response rates
In 2011, 416 of the 643 invited patients returned Q1 (response 65%). Of these 416, 
413 patients were invited to fill out the second questionnaire (Q2) after a period of at 
least two weeks. Of the remaining 3 patients, one objected to fill out any additional 
questionnaires beforehand and two had returned an incomplete Q1. Q2 was completed 
by 389 patients (response 94%, see also Fig. 1). The median number of days between 
filling out Q1 and Q2 was 31 (range 15-133).
 
Reproducibility in all patients
In Table 2, characteristics of all  the patients included are shown. The median time 
since diagnosis at the time of filling out Q1 was 2.2 years (range 1.0-21.6). Most 
patients (260 of 389) were diagnosed 1.5-3.0 years before Q1.
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In Tables 3A and B, the questionnaire items are presented with their reproducibility 
coefficients and 95% confidence intervals for all patients (see also Fig. 2) and for the 
different subgroups (i.e. sex, age group, education level, time between questionnaires, 
time since diagnosis). In all patients, the items concerning phenotypic characteristics 
showed the highest reproducibility coefficient, with a median κw of 0.64 and a range 
of 0.62 (skin colour) to 0.77 (freckle density on the face), indicating substantial 
 reproducibility. The items related to sun exposure and sun protection behaviour had 
a median κ/κw/ICC of 0.50 with a wide range of 0.38 (hours outside during weekends 
as adult) to 0.79 (use of solariums), indicating a fair-to-substantial reproducibility. 
The items regarding sun burn history had a median κw of 0.47 and a range of 0.43 
(mildly burned as adult) to 0.51 (mildly burned <18th), also indicating a moderate 
 reproducibility.
Reproducibility in subgroups
In the subgroup analyses, we found that patients younger than 40 had a reproducibility 
at least 0.20 higher in nine out of 29 items, compared with patients aged 40-70 (items 
9a, 9b, 10, 11, 12e, 13b, 14, 15, all in the sun behaviour category and items 16 and 19 in the 
sun burn category; Table 3). The patients aged 40-70 also had a higher reproducibility 
in seven out of 29 items compared with the eldest group (>70, items 8a, 8b, 8c, 19, 
12d, 13b in the sun behaviour category and item 17 in the sun burn category). 
Patients with a higher education had a better reproducibility compared with patients 
with a lower education in four out of 29 questions (items 9b, 12a, 14 and 15, all in the 
sun behaviour category; Table 4). In the stratified analysis for time since diagnosis, 
we found that for four out of 29 items, patients with a diagnosis <1.5 years ago had 
higher scores compared with patients with a diagnosis 1.5-3.0 years ago (item 6 in 
the phenotypic characteristics category, and items 9a, 9b and 10 in the sun behaviour 
category; Table 4). Between the patients with a diagnosis 1.5-3.0 years and patients 
Figure 1  Schematic overview of the invitation and response of Questionnaire 1 (Q1) and 
Questionnaire 2 (Q2).
* One respondent of questionnaire 1 wished 
   not to be invited for questionnaire 2 and two other 
   respondents had an incomplete questionnaire 1.
643 patients 
invited for 
participation 
in study
416 patients
returned Q1
(65% response)
413* patients
invited for Q2
389 patients
returned Q2
(94% response)
and were included 
in there 
producibility 
analysis
Table 2  Characteristics of patients included in the reproducibility analysis.
Patients who completed  
Q1 and Q2 (n=389)
Median age at time of Q1, years (range) 57 (20-82)
Median time since diagnosis, years (range) 2.2 (1.0-21.6)
n (%)
Gender Male
Female
146 (37.5)
243 (62.5)
Education level Primary school
Secondary education (academic, 
vocational or technical)
Postsecondary education (college, 
university, vocational or technical)
20 (5.1)
155 (39.8)
214 (55.0)
Melanoma subtype Superficial spreading melanoma
Nodular melanoma
Lentigo maligna melanoma
Acrolentiginous melanoma
Melanoma in situ
Lentigo maligna
Melanoma NOS
Other/unknown
237 (60.9)
22 (5.7)
17 (4.4)
3 (0.8)
50 (12.9)
24 (6.2)
33 (8.5)
3 (0.8)
Abbreviations: Q1, questionnaire 1; Q2, questionnaire 2
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Table 3   Questionnaire items and reproducibility coefficients with their 95% confidence intervals  
or standard error, for all patients and subgroups according to gender and age group.
Questionnaire itema N b All cases Gender Age group
Men Women <40 year 40-70 year >70 year
n=389 n=146 n=243 n=49 n=277 n=63
Phenotypic characteristics
1 .Skin colour 387 0.62 (0.55-0.70) 0.66 (0.54-0.77) 0.60 (0.50-0.69) 0.55 (0.32-0.78) 0.65 (0.56-0.73) 0.53 (0.36-0.72)
2. Skin reaction 389 0.63 (0.56-0.70) 0.67 (0.56-0.79) 0.61 (0.52-0.70) 0.63 (0.42-0.83) 0.63 (0.55-0.72) 0.63 (0.45-0.81)
3. Tanning ability 389 0.74 (0.69-0.80) 0.75 (0.66-0.84) 0.73 (0.66-0.80) 0.81 (0.67-0.95) 0.76 (0.69-0.82) 0.62 (0.47-0.77)
4. Freckle density face 355 0.77 (0.72-0.82) 0.69 (0.59-0.79) 0.80 (0.74-0.86) 0.84 (0.72-0.95) 0.77 (0.72-0.83) 0.66 (0.49-0.82)
5. Freckle density arms 353 0.64 (0.59-0.70) 0.63 (0.53-0.73) 0.65 (0.58-0.72) 0.78 (0.65-0.90) 0.61 (0.54-0.68) 0.68 (0.53-0.83)
6. Nevus patterns 362 0.62 (0.56-0.69) 0.65 (0.55-0.76) 0.61 (0.53-0.69) 0.62 (0.46-0.77) 0.59 (0.51-0.67) 0.54 (0.35-0.74)
Sun behaviour
7. Use of solariums 383 0.79 (0.75-0.84) 0.74 (0.64-0.84) 0.80 (0.76-0.86) 0.82 (0.72-0.93) 0.78 (0.73-0.84) 0.75 (0.58-0.92)
8. Protection methods <18th 
a) Protective clothing
b) Hat
c) Sun screen lotion
d) Shadow
e)  Avoiding the sun between 11 and 15h
371
367
377
369
376
0.42 (0.34-0.51)
0.42 (0.32-0.53)
0.50 (0.42-0.57)
0.46 (0.37-0.54)
0.51 (0.42-0.60)
0.37 (0.25-0.49)
0.44 (0.30-0.59)
0.55 (0.43-0.67)
0.49 (0.34-0.64)
0.45 (0.30-0.59)
0.45 (0.34-0.56)
0.41 (0.28-0.55)
0.46 (0.36-0.56)
0.44 (0.33-0.54)
0.54 (0.43-0.64)
0.41 (0.23-0.59)
0.49 (0.26-0.71)
0.50 (0.34-0.66)
0.55 (0.37-0.73)
0.56 (0.32-0.81)
0.46 (0.36-0.57)
0.45 (0.33-0.58)
0.52 (0.42-0.61)
0.47 (0.36-0.57)
0.53 (0.43-0.63)
0.24 (0.06-0.42)
0.21 (-0.03-0.45)
0.31 (0.13-0.49)
0.38 (0.12-0.63)
0.38 (0.16-0.61)
9. Hours outside < 18th 
a) On schooldays
b) During weekends and holidays
372
370
0.44 (0.36-0.53)
0.49 (0.41-0.58)
0.47 (0.33-0.60)
0.44 (0.29-0.60)
0.43 (0.32-0.54)
0.51 (0.41-0.61)
0.61 (0.41-0.81)
0.72 (0.52-0.91)
0.41 (0.30-0.51)
0.44 (0.36-0.52)
0.47 (0.26-0.67)
0.36 (0.14-0.59)
10. Sun holidays < 18th c 386 0.57 (SE=0.035) 0.58 (SE=0.057) 0.56 (SE=0.045) 0.79 (SE=0.094) 0.58 (SE=0.042) 0.35 (SE=0.092)
11.  Sun holidays < 18th : weeks per year d, e 162 0.70 (0.61-0.77) 0.80 (0.68-0.88) 0.66 (0.54-0.76) 0.84 (0.70-0.91) 0.61 (0.49-0.72) 0.45 (-0.08-0.78)
12. Protection methods (adult) 
a) Protective clothing
b) Hat
c) Sun screen lotion
d) Shadow
e)  Avoiding the sun between 11 and 15h
368
369
372
374
369
0.45 (0.37-0.53)
0.56 (0.50-0.63)
0.51 (0.44-0.57)
0.52 (0.45-0.59)
0.40 (0.32-0.48)
0.51 (0.39-0.64)
0.52 (0.42-0.62)
0.49 (0.38-0.60)
0.47 (0.35-0.70)
0.42 (0.30-0.54)
0.40 (0.31-0.49)
0.58 (0.50-0.66)
0.48 (0.40-0.56)
0.56 (0.47-0.65)
0.39 (0.29-0.49)
0.37 (0.19-0.55)
0.59 (0.43-0.74)
0.41 (0.23-0.60)
0.46 (0.27-0.65)
0.18 (0.00-0.37)
0.48 (0.39-0.56)
0.57 (0.49-0.65)
0.49 (0.42-0.57)
0.56 (0.48-0.65)
0.46 (0.37-0.55)
0.38 (0.14-0.61)
0.51 (0.36-0.66)
0.54 (0.36-0.72)
0.36 (0.19-0.52)
0.27 (0.09-0.44)
13. Hours outside (adult)
a) On workdays
b) During weekends and holidays
380
363
0.46 (0.38-0.54)
0.38 (0.29-0.47)
0.57 (0.45-0.70)
0.31 (0.16-0.45)
0.39 (0.29-0.50)
0.42 (0.30-0.53)
0.56 (0.33-0.79)
0.74 (0.57-0.92)
0.45 (0.36-0.54)
0.39 (0.28-0.49)
0.39 (0.19-0.60)
0.11 (-0.02-0.31)
14. Sun holidays (adult) c 386 0.62 (SE=0.054) 0.65 (SE=0.082) 0.60 (SE=0.071) 0.83 (SE=0.113) 0.59 (SE=0.065) 0.63 (SE=0.129)
15. Sun holidays (adult): weeks per year d,e 296 0.52 (0.43-0.60) 0.67 (0.55-0.76) 0.49 (0.38-0.59) 0.89 (0.79-0.94) 0.36 (0.24-0.47) 0.39 (0.10-0.61)
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Table 3   Continued.
Questionnaire itema N b All cases Gender Age group
Men Women <40 year 40-70 year >70 year
n=389 n=146 n=243 n=49 n=277 n=63
Sun burn history
16. Mildly burned < 18th 384 0.51 (0.43-0.60) 0.51 (0.37-0.65) 0.51 (0.41-0.62) 0.76 (0.58-0.95) 0.52 (0.42-0.62) 0.34 (0.13-0.55)
17. Severely burned <18th 387 0.50 (0.40-0.59) 0.45 (0.29-0.60) 0.53 (0.41-0.64) 0.61 (0.38-0.83) 0.51 (0.41-0.62) 0.31 (0.07-0.55)
18. Mildly burned (adult) 381 0.43 (0.34-0.52) 0.40 (0.26-0.55) 0.45 (0.34-0.55) 0.49 (0.22-0.75) 0.46 (0.36-0.56) 0.29 (0.07-0.50)
19. Severely burned (adult) 388 0.45 (0.36-0.55) 0.41 (0.22-0.59) 0.48 (0.37-0.59) 0.74 (0.57-0.92) 0.44 (0.33-0.54) 0.38 (0.09-0.67)
Abbreviations: SE, standard error; ICC, intraclass correlation coefficient
a   For all questions, the reproducibility is expressed in Cohen’s weighted kappa (κw) with its 95% confidence  
interval, unless otherwise stated.
b  Only patients that filled out the question in both questionnaires were included in the reproducibility analysis.
Table 4   Questionnaire items and reproducibility coefficients with 95% confidence  
intervals or standard errors, for subgroups according to education level,  
time between Questionnaire 1 (Q1) and 2 (Q2) and time since diagnosis.
Questionnaire itema Education level Time between questionnaires Time since diagnosis
Primary  
or secondary 
education
Postsecondary 
education
≤31 days >31 days <1.5 years 1.5-3.0 years >3.0 years
n=175 n=214 n= 198 n=191 n=44 n=260 n=84
Phenotypic characteristics
1. Skin colour 0.60 (0.49-0.71) 0.64 (0.54-0.74) 0.64 (0.54-0.74) 0.60 (0.49-0.71) 0.51 (0.28-0.75) 0.63 (0.54-0.71) 0.65 (0.50-0.80)
2. Skin reaction 0.56 (0.45-0.67) 0.70 (0.60-0.79) 0.63 (0.53-0.72) 0.64 (0.54-0.74) 0.61 (0.39-0.83) 0.64 (0.55-0.72) 0.61 (0.45-0.77)
3. Tanning ability 0.75 (0.68-0.83) 0.73 (0.65-0.81) 0.74 (0.66-0.81) 0.75(0.67-0.83) 0.59 (0.40-0.77) 0.76 (0.69-0.82) 0.77 (0.65-0.88)
4. Freckle density face 0.75 (0.67-0.83) 0.78 (0.71-0.84) 0.75 (0.68-0.83) 0.78 (0.71-0.85) 0.82 (0.71-0.94) 0.74 (0.67-0.80) 0.82 (0.73-0.92)
5. Freckle density arms 0.63 (0.53-0.73) 0.65 (0.58-0.72) 0.67 (0.60-0.75) 0.61 (0.52-0.70) 0.62 (0.45-0.78) 0.63 (0.55-0.70) 0.71 (0.60-0.82)
6. Nevus patterns 0.57 (0.47-0.67) 0.64 (0.56-0.72) 0.58 (0.48-0.67) 0.67 (0.58-0.75) 0.72 (0.55-0.88) 0.58 (0.50-0.66) 0.38 (0.55-0.81)
Sun behaviour
7. Use of solariums 0.75 (0.67-0.82) 0.83 (0.77-0.90) 0.79 (0.72-0.86) 0.80 (0.73-0.86) 0.88 (0.80-0.96) 0.80 (0.74-0.85) 0.74 (0.61-0.87)
8. Protection methods <18th 
a) Protective clothing
b) Hat
c) Sun screen lotion
d) Shadow
e)  Avoiding the sun between 
11 and 15h
0.35 (0.22-0.48)
0.39 (0.22-0.56)
0.41 (0.29-0.53)
0.42 (0.29-0.56)
0.58 (0.46-0.69)
0.49 (0.39-0.59)
0.45 (0.34-0.57)
0.58 (0.49-0.68)
0.49 (0.37-0.61)
0.44 (0.32-0.57)
0.45 (0.33-0.57)
0.54 (0.39-0.69)
0.44 (0.33-0.56)
0.44 (0.31-0.57)
0.48 (0.35-0.61)
0.39 (0.28-0.51)
0.32 (0.21-0.43)
0.55 (0.44-0.65)
0.47 (0.35-0.60)
0.53 (0.41-0.65)
0.41 (0.33-0.69)
0.38 (0.14-0.61)
0.55 (0.41-0.69)
0.44 (0.24-0.65)
0.63 (0.40-0.86)
0.43 (0.33-0.53)
0.44 (0.32-0.56)
0.51 (0.42-0.60)
0.48 (0.37-0.58)
0.52 (0.41-0.62)
0.37 (0.17-0.57)
0.41 (0.16-0.65)
0.44 (0.26-0.63)
0.41 (0.21-0.61)
0.51 (0.31-0.70)
c  Cohen’s Kappa (κ).
d  Intraclass Correlation Coefficient (ICC).
e  In items 11 and 15 only patients who answered the previous question with ‘yes’ were included.
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Table 4   Continued.
Questionnaire itema Education level Time between questionnaires Time since diagnosis
Primary  
or secondary 
education
Postsecondary 
education
≤31 days >31 days <1.5 years 1.5-3.0 years >3.0 years
n=175 n=214 n= 198 n=191 n=44 n=260 n=84
Sun behaviour
9. Hours outside < 18th 
a) On schooldays
b)  During weekends and 
holidays
0.39 (0.26-0.51)
0.38 (0.25-0.51)
0.46 (0.34-0.58)
0.59 (0.47-0.70)
0.39 (0.26-0.51)
0.42 (0.30-0.54)
0.49 (0.38-0.61)
0.56 (0.45-0.68)
0.66 (0.46-0.87)
0.73 (0.53-0.93)
0.40 (0.30-0.51)
0.44 (0.33-0.54)
0.46 (0.27-0.64)
0.53 (0.36-0.71)
10. Sun holidays < 18th b 0.54 (SE=0.052) 0.57 (SE=0.052) 0.52 (SE=0.051) 0.62 (SE=0.049) 0.79 (SE=0.084) 0.54 (SE=0.044) 0.54 (SE=0.078)
11. Sun holidays < 18th: 
weeks per year c, d
0.75 (0.60-0.85) 0.64 (0.51-0.74) 0.71 (0.59-0.81) 0.69 (0.55-0.79) 0.85 (0.67-0.94) 0.72 (0.61-0.80) 0.23 (-0.08-0.50)
12. Protection methods 
(adult) 
a) Protective clothing
b) Hat
c) Sun screen lotion
d) Shadow
e)  Avoiding the sun between 
11 and 15h
0.39 (0.28-0.50)
0.60 (0.51-0.69)
0.53 (0.44-0.62)
0.52 (0.43-0.62)
0.37 (0.24-0.49)
0.64 (0.56-0.73)
0.54 (0.45-0.63)
0.48 (0.39-0.58)
0.51 (0.40-0.62)
0.43 (0.33-0.53)
0.41 (0.31-0.51)
0.57 (0.49-0.65)
0.49 (0.40-0.58)
0.51 (0.42-0.61)
0.44(0.34-0.54)
0.48 (0.38-0.59)
0.55 (0.45-0.65)
0.52 (0.42-0.62)
0.52 (0.41-0.64)
0.35 (0.23-0.47)
0.48 (0.28-0.68)
0.56 (0.37-0.75)
0.48 (0.26-0.71)
0.41 (0.24-0.57)
0.48 (0.31-0.66)
0.50 (0.41-0.59)
0.56 (0.48-0.64)
0.52 (0.44-0.59)
0.52 (0.44-0.61)
0.39 (0.29-0.48)
0.29 (0.14-0.44)
0.57 (0.43-0.70)
0.47 (0.33-0.62)
0.54 (0.37-0.71)
0.41 (0.24-0.57)
13. Hours outside (adult)
a) On workdays
b)  During weekends and 
holidays
0.44 (0.32-0.55)
0.29 (0.15-0.42)
0.43 (0.32-0.55)
0.47 (0.35-0.60)
0.45(0.34-0.57)
0.35 (0.22-0.48)
0.47 (0.36-0.58)
0.41 (0.29-0.54)
0.43 (0.24-0.63)
0.45 (0.18-0.73)
0.43 (0.33-0.52)
0.31 (0.20-0.42)
0.56 (0.38-0.73)
0.53 (0.36-0.71)
14. Sun holidays (adult) b 0.50 (SE=0.084) 0.74 (SE=0.065) 0.66 (SE=0.070) 0.58 (SE=0.082) 0.73 (SE=0.144) 0.59 (SE=0.068) 0.66 (SE=0.103)
15. Sun holidays (adult): 
weeks per year c,d
0.39 (0.23-0.53) 0.77 (0.70-0.82) 0.61 (0.50-0.71) 0.49 (0.35-0.60) 0.81 (0.65-0.90) 0.40 (0.28-0.51) 0.80 (0.67-0.87)
Sun burn history
16. Mildly burned <18th 0.45 (0.32-0.58) 0.57 (0.45-0.68) 0.46 (0.33-0.58) 0.57 (0.45-0.69) 0.56 (0.30-0.82) 0.48 (0.38-0.59) 0.58 (0.40-0.76)
17. Severely burned <18th 0.49 (0.35-0.63) 0.50 (0.38-0.63) 0.45 (0.32-0.58) 0.54 (0.42-0.67) 0.57 (0.29-0.84) 0.50 (0.39-0.61) 0.45 (0.25-0.65)
18. Mildly burned (adult) 0.43 (0.30-0.57) 0.42 (0.31-0.53) 0.44 (0.31-0.56) 0.42 (0.30-0.54) 0.44 (0.58-0.61) 0.43 (0.32-0.55) 0.40 (0.25-0.56)
19. Severely burned (adult) 0.52 (0.37-0.66) 0.39 (0.27-0.50) 0.52 (0.38-0.66) 0.38 (0.25-0.51) 0.52 (0.34-0.70) 0.46 (0.34-0.58) 0.42 (0.20-0.63)
Abbreviations: 95% CI, 95% confidence interval; SE, standard error
a   For all questions, the reproducibility is expressed in Cohen’s weighted kappa (κw) with its 95% confidence 
interval, unless otherwise stated.
b  Cohen’s Kappa (κ).
c  Intraclass Correlation Coefficient (ICC). 
d  In items 11 and 15 only patients who answered the previous question with ‘yes’ were included.
66 67
CHAPTER 3 REPRODUCIBILITY OF SELF-REPORTED MELANOMA RISK FACTORS
3
with a diagnosis >3.0 years, a higher reproducibility was found for three out of 29 
items (item 6, phenotypic characteristics, and items 11 and 12a, sun behaviour) and 
a lower score for two out of 29 items (items 13b and 15, sun behaviour). Between men 
and women, no clear differences were observed.
Because of the wide range in the time between the two questionnaires, an additional 
stratified analysis was carried out comparing the reproducibility of questions for the 
time between questionnaires being ≤31 days versus >31 days. No differences were 
observed between these groups. All reported differences between subgroups were 
statistically significant.
Discussion
We showed that the reproducibility of a questionnaire on melanoma risk factors 
varied from fair-to-substantial. It was best in questionnaire items regarding phenotypic 
characteristics, followed by those regarding sun exposure and sun protection 
behaviour, and sunburn history. Younger patients and patients with a higher education 
appear to have a slightly better reproducibility compared to older patients and 
patients with a lower education, respectively. Patients with a shorter time since the 
diagnosis had a slightly better reproducibility. These findings have to be interpreted 
with care, as for the majority of questions, no relevant differences were observed. No 
clear differences were observed between men and women.
Our findings are consistent with the few studies that investigated a similar study 
population, that is melanoma patients. Weinstock et al. (1991) studied the reproducibility 
of two melanoma risk factors in 143 female melanoma cases from the Nurses’ Health 
Study in Massachusetts, USA. Of these women, 87 had a melanoma before the first 
questionnaire, and 34 developed a melanoma during follow-up, after completing 
the first questionnaire. The time between questionnaires was two to four years. They 
investigated the reproducibility of ‘natural hair colour at age 21’ and ‘tanning ability 
after repeated sun exposure as a child or adolescent’. The Spearman correlation 
coefficients (rs) that they found in prevalent cases were rs=0.82 (hair colour), and 
rs =0.78 (tanning ability) [8], which seems higher than in our study. However, the 
Spearman correlation coefficient is a different outcome measure which is often higher 
than a κ, κw or ICC. This makes it difficult to compare their results directly with ours. 
Also, the time between questionnaires was much longer. A small study performed by 
Berwick and Chen (1995) included 50 melanoma cases from Connecticut, USA. They 
investigated only five items concerning sun burns (ever burned, κ=0.37, first burn, 
ICC=0.34, last burn, ICC=0.42), freckles (ever freckled, κ=0.57) and tanning ability 
(ICC=0.41) [6]. Compared with similar questionnaire items in the present study, they 
report a lower reproducibility. The time between questionnaires was one to three 
years, which could partly explain this.
Another small study performed in 2005 by Beane Freeman et al. included 45 
melanoma cases and reported a better reproducibility than we did, especially on 
sunburn history (κ=0.67-0.77) and sunscreen use (κw=0.60-0.81) [5]. The time 
between questionnaires was two to four weeks, which is shorter than in the present 
study (median time 31 days). This could partly explain the better reproducibility in this 
study. Parr et al. (2008) included 162 melanoma cases in the Norwegian Women and 
Cancer study and found a slightly better reproducibility for phenotypic characteristics 
(κw=0.89 for eye colour), but a lower value for solarium use (κw=-0.01 to 0.46) 
Figure 2  Reproducibility coefficients with error bars indicating the 95% confidence intervals 
for all questionnaire items, for all patients. The dashed lines indicate the boundaries as suggested 
by Landis and Koch (1977).
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compared to the present study. The mean time between questionnaires was 11 years, 
which is much longer than in the present study [7]. It is unclear how the time between 
questionnaires influenced the outcome in the different studies. One would expect 
that with very long periods between questionnaires, the reproducibility will be worse, 
especially for questions concerning sun exposure, where recall is important, but this 
is not the case in all studies.
Other groups investigated questionnaires on skin cancer risk factors in other study 
populations, for example non-melanoma skin cancer patients [10, 11], or healthy 
subjects [12-18], with a reproducibility ranging from fair to good, depending on the 
type of question. As no direct comparisons were made between melanoma patients 
and other skin cancer patients, it is difficult to say whether the reproducibility differs 
between these patient groups. It is possible though, that due to a higher prevalence 
of sun exposure in skin cancer patients, κ values are lower due to an nonequiprobable 
distribution of scores [19].
In the present study, the reproducibility was best for the questions concerning phenotypic 
characteristics, followed by the questions concerning sun behaviour. This finding was 
also reported by other study groups [5, 11, 13, 15, 17]. An explanation for this may be 
that people can check their skin colour or current mole density and do not have to recall 
this, contrary to questions regarding sun protection methods or sun burn history. However, 
the validity of some of these items can be debated, as reported information on freckle 
and nevus density before the age of 18, is likely to be influenced by self-assessment at 
older ages, when data collection took place. Since nevus counts are reported to 
decrease with age [20], patients may have underestimated their nevus counts. However, 
this was only the case in selected patients, and we expect that this decrease in nevi was 
probably not sufficient to lead to a change in nevus density category.
In the subgroup analyses, younger patients appear to have a slightly better reproducibility 
of the items concerning sun behaviour and sun burn history, compared to older patients. 
This finding may be explained by a better memory of younger patients or by the fact 
that the time to remember is shorter for younger patients. Also, we observed that 
patients with a higher education had slightly better scores on the items concerning 
sun behaviour than patients with a lower education. A possible explanation might be a 
better understanding of the questions of the higher educated. The time since melanoma 
diagnosis did seem to diminish the reproducibility, which may be explained by 
confusion of behaviour before and after the diagnosis. To the best of our knowledge, 
no other studies reported a reproducibility analysis for time since diagnosis. This may 
be something to take into account when selecting patients for a study in which this 
type of questionnaires is used.
A few other studies performed subgroup analyses with contradictory results. Rosso 
et al. found that a high level of education was associated with a lack of agreement in 
some questions, but no differences were observed between different age groups 
and sexes [11]. In the study of Van der Mei et al., reproducibility did not differ by age 
at interview, sex or education level [21]. Veierod et al. [17] showed that the kappa 
increased by education level, though only for a question on freckling. There was no 
indication for heterogeneity across ages. Compared to the studies above, we found 
more pronounced differences between subgroups according to age and education. 
Between-study comparisons are difficult, however, because different analyses were 
performed, and the content of and the time between questionnaires differ.
In this study, we were able to include a large series of 389 melanoma patients, which 
made subgroup analyses possible. The results from this study can therefore be a valuable 
addition to the existing literature. Previous research showed inconsistent results 
comparing the reproducibility between cases and controls [6-8, 22]. As we did not 
administer the same questionnaire twice in controls, we were not able to study 
differences in reproducibility between melanoma patients and controls, and thus 
assess indications of recall bias. However, previous studies that used questionnaire 
data did find associations between sun exposure and melanoma risk [3]. Under the 
assumption that differences in recall between cases and controls would cause a bias 
towards the null, associations may be stronger in reality. The time between filling out 
Q1 and Q2 varied between 15 and 133 days, however, this did not seem to have an 
effect on the reproducibility.
Conclusion
With this study, we showed that the reproducibility of questionnaire items depends on 
the subject of the question and varies somewhat among different age groups and 
education levels. It is advised that researchers take this into account when they use 
questionnaires as a tool for data collection, and continue to report the quality of their 
questionnaires.
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Abstract
Background 
Melanoma patients are at increased risk of developing subsequent primary melanomas. 
Knowledge about risk factors for these subsequent primaries is scarce. More evidence 
may help clinicians in tailoring surveillance schedules.
Methods 
A population-based series of cutaneous melanoma patients, diagnosed between 
2003 and 2011 in the eastern part of the Netherlands, completed a questionnaire on 
demographic and phenotypic characteristics, family history of cancer and sun exposure 
(n=1127). Baseline patient and tumour characteristics were extracted from the 
Netherlands Cancer Registry and supplemented with additional clinical information 
from medical files. The 5-year cumulative risk and conditional cumulative risk of 
developing a second primary in year 5-10 after diagnosis of the first melanoma were 
calculated using Kaplan-Meier analysis. Multivariable proportional hazards analyses 
were performed to identify risk factors for second primary melanoma. 
Results
Fifty-three patients were diagnosed with at least one second primary melanoma 
during a median follow-up time of 7.3 years. The 5-year cumulative risk was 3.7% 
(95% confidence interval (CI): 2.5-4.9%). The conditional cumulative risk of developing 
a second melanoma in year 5-10 was 4.6% (95% CI: 2.3-6.9%). The risk of a second 
primary melanoma increases with older age at diagnosis of the first melanoma 
(hazard ratio (HR) 1.04 per year; 95% CI 1.01-1.07) and was also higher in patients 
with a high nevus density (HR 5.35; 95% CI 2.20-12.98) and in patients who had 
worked outside for more than 10 years (HR 2.16, 95% CI 1.04-4.51). Patients with invasive 
melanoma > 1 mm had a decreased risk compared to patients with melanoma in situ 
(HR 0.4; 95%CI:0.2-0.98).
 
Conclusions 
Our findings suggest that in addition to phenotypic characteristics, cumulative sun 
exposure increases the risk of second primary melanomas. Patients with melanoma 
in situ may need to be offered follow-up, which is currently not advised in guidelines. 
Since the risk of developing second primary melanomas remained as high after 5 to 
10 years of follow-up as it is in the first 5 years, a subgroup of patients may need a 
longer follow-up than is advised in the latest Dutch guideline. 
Introduction
Patients with melanoma have an increased risk of developing additional primary 
melanomas: population-based studies report 5-year cumulative risks ranging from 2 
to 4.5 percent [1-3]. The risk of a second melanoma is highest during the first year 
after the initial diagnosis, but remains elevated for up to 20 years [3, 4]. 
 From previous studies it is known that risk factors for multiple primary melanoma 
include high normal or dysplastic nevus counts and a positive family history for 
melanoma [5-9]. Germline mutations of the CDKN2A gene were also associated with 
multiple primary melanoma, which partly explains the higher risk in patients with a 
positive family history for melanoma [5, 6]. 
 Studies also reported a positive association between sun exposure and (non)
use of sunscreen and the risk of multiple primary melanoma [1, 3, 6, 9-12]. Kricker et 
al. performed detailed analyses of lifetime UV exposure and found that the risk of 
multiple primary melanomas increased with ambient UV irradiance at place of 
residence, and that the risk increased with lifetime recreational sun exposure [12].
 Many studies that aimed to identify risk factors for second or multiple primary 
melanoma were restricted to patients selected from a single centre and focused on a 
limited set of potential risk factors. In the literature, second or multiple primary 
melanoma often includes both synchronous and metachronous primary melanomas. 
When investigating risk factors for subsequent melanomas, it is important to make a 
distinction between the two, as only metachronous lesions are of interest during 
follow-up of melanoma patients in daily clinical practice. 
 We performed a study in a Dutch population-based series of melanoma patients, 
aimed at finding novel risk factors for second (metachronous) primary melanoma. 
We included information on sun exposure, phenotypic characteristics and histo-
pathological features. The results of this study may help clinicians with identifying 
patients at higher risk of second primary melanomas so that tailored follow-up may 
become possible. 
Methods
Patients
The present study was part of an ongoing population-based study on the association 
of genetic variants and lifestyle-related factors with the risk and prognosis of 
melanoma. In total, 1808 Dutch melanoma patients were invited for this study through 
the population-based Netherlands Cancer Registry (NCR). All patients lived in the 
eastern part of the Netherlands and were diagnosed with an in situ or invasive 
melanoma (International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) 
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topography codes C44 and C80.9, and morphology codes 8720-8780) in the period 
2003-2011. For the current study, all patients who filled out a questionnaire on general 
health, melanoma risk factors and family history of cancer, and had a first primary 
cutaneous melanoma between 2003 and 2011 (N=1127 patients) were included. 
Participating patients gave informed consent for retrieval of information from medical 
records and approval for the study was given by the local Medical Ethics Committee.
Outcome
The outcome of interest was the diagnosis of a metachronous second primary 
melanoma, defined as as a primary melanoma, diagnosed at least 30 days after the 
first melanoma, and identified through the NCR or medical files. Second primary 
melanomas diagnosed within 30 days after the first melanoma were considered 
synchronous and excluded from analyses. This 30-day period was previously described 
in the literature [8, 9] and is also used by the NCR to distinguish between multifocal 
tumours and subsequent primaries. Person-time at risk was calculated as the time 
between the first primary melanoma and diagnosis of the second primary melanoma, 
date of death or date of last follow-up, whichever came first.
Variables
Date of birth, gender, date of diagnosis of the first primary melanoma and date of 
death were derived from the NCR. Included tumour characteristics, derived from the 
NCR, medical records and pathology reports, were histological subtype (superficial 
spreading, lentigo maligna (melanoma), nodular or other), topography (scalp, neck, 
face, trunk, limbs) and Breslow thickness for invasive tumours (0-1 mm, 1-2mm, 
2-4mm, >4mm). Tumour information was derived from the NCR, medical records 
and pathology reports. 
 Information retrieved from the self-administered questionnaires included race, 
highest level of completed education, marital status, BMI, smoking status, alcohol 
consumption, hair colour, eye colour, nevus density, freckling of the face and freckling 
of the arm between the age of 13 and 18 years, residence in a subtropical country for 
at least 1 year, having a job outside and its duration, number of severe and number 
of moderate sunburns during child- and adulthood respectively, sun bed use, sunny 
holidays for at least 2 weeks per year, the use of sun protection measures during 
childhood and adulthood, and family history of skin cancer. See Table 1 for the 
subcategories of each variable. Level of education was defined as the highest level 
of completed education: low (primary school graduate), moderate (secondary school 
or vocational graduate) or high (post secondary graduate or higher). Nevus density 
and freckling on the face and arm were scored by the patient using cartoons (see Fig. 1).
The use of sun protection measures was calculated as a composite score of five 
questionnaire items: the use of a) protective clothing, b) a hat, or c) sunscreen, d) seeking 
shadow, and e) avoiding sun-exposure between 11 AM and 3 PM. These items were 
combined to reduce the number of variables. Each question had 5 answer categories 
(never, rarely, sometimes, often, always) and never was scored as 0 and always as 4. 
When the sum score of these questions was below 5, the variable was categorized as 
‘never-rarely’, a score ranging from 5 to 9 was categorized as ‘rarely- sometimes’, a 
score ranging from 10 to 14 as ‘sometimes-often’ and 15 or more as ‘often-always’. 
 A positive family history of skin cancer was defined as having one or more first- 
degree relatives with skin cancer. All patients who reported a family member with skin 
cancer were approached again by telephone to distinguish between melanoma and 
non-melanoma skin cancer. Unfortunately, part of the patients could not be reached 
Figure 1  Categories of freckle and nevus density as depicted in the questionnaire.
Freckles on the face
None                               Some                               Quite a few                             Many
Freckles on the arm
None                               Some                               Quite a few                             Many
Nevus density
None                               Some                               Quite a few                             Many
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and of those patients that were reached, many were unable to make the distinction 
between melanoma or non-melanoma skin cancer in their relatives. We therefore 
chose to define this variable as ‘family history of skin cancer’. 
Analyses
The cumulative 5-year risk of developing a second primary melanoma was calculated 
using Kaplan-Meier analysis. In order to evaluate the need for extended follow-up 
after 5 years (as advised in the Dutch melanoma guideline), the conditional cumulative 
risk of developing a melanoma in year 5-10 after diagnosis of the first melanoma was 
calculated for patients who did not develop a second melanoma in the first 5 years 
after diagnosis. 
 Univariable Cox regression analyses were carried out. Hazard ratios (HR) and 
corresponding 95% Confidence Intervals (CI) for developing a second primary melanoma 
were estimated. For some variables, categories were combined before inclusion in the 
Cox regression analysis to obtain higher statistical power. Ulceration was scored as ‘no’ 
for in situ melanomas, so that these patients would not be excluded from the model. 
For the same reason, in situ was scored as a separate category in the Breslow variable. 
 In addition, a multivariable Cox regression analysis was performed. Risk factors 
that were known from the literature and all variables with a p-value of <0.10 in the 
univariable analyses were included in the multivariable model.
Multiple imputation was performed to handle missing data using the fully conditional 
specification (FCS) method in IBM SPSS Statistics. Imputations were repeated ten 
times. All Cox regression analyses were carried out with imputed data. Analyses were 
performed using IBM SPSS Statistics 20 and statistical significance was indicated by 
a 2-tailed p-value of < 0.05.
Results
Patients had a median age of 52.3 years, 434 (38.5%) were male and 693 (61.5%) 
female. Overall, 53 of 1127 melanoma patients developed a metachronous second 
primary melanoma during a median follow-up time of 7.3 years. The 5-year cumulative 
risk of a second primary was 3.7% (95% CI: 2.5-4.9%). The conditional cumulative risk of 
developing a second melanoma in year 5-10 of follow-up was 4.6% (95% CI: 2.3-6.9%). 
Thirty-three percent of second primary melanomas were diagnosed 5 years or more 
after the first melanoma.
Table 1  Patient and tumour characteristics of original and imputed data (n=1127).
Variable Categories N (%) N (%) after  
imputation
Gender Male
Female
434 (38.5)
693 (61.5)
Mean age at diagnosis, 
years (SD)
- 52.3 (13.2)
Age categories <40 years
40-60 years
≥60 years
226 (20.1)
535 (47.5)
366 (32.5)
Melanoma subtype SSM
NM
LM(M)
Other 
760 (67.4)
76 (6.7)
113 (10.0)
178 (15.8)
Body site Head/neck
Trunk
Extremities
Missing
164 (14.6)
405 (35.8)
556 (49.3)
4 (0.4)
165 (14.6)
405 (35.9)
557 (49.4)
Tumour ulceration No
Yes
Missing
832 (73.8)
56 (5.0)
239 (21.2)
1025 (90.9)
102 (9.1)
Breslow categories In situ
≤1.00 mm
1.01-2.00 mm
2.01-4.00 mm
>4.00 mm
Missing
219 (19.4)
565 (50.1)
222 (19.7)
85 (7.5)
27 (2.4)
9 (0.8)
219 (19.4)
568 (50.4)
224 (19.9)
85 (7.5)
31 (2.8)
Marital status Single
With partner
Other
182 (16.1)
931 (82.6)
14 (1.2)
Education level Low
Moderate
High
Missing
460 (40.8)
302 (26.8)
359 (31.9)
6 (0.5)
462 (41.0)
304 (2.7)
361 (32.0)
BMI category Normal 
Overweight
Obese
Missing 
642 (57.0)
399 (35.4)
77 (6.8)
9 (0.8)
645 (57.2)
404 (35.8)
78 (6.9)
Smoking status None smoker
Ex-smoker
Current smoker
Missing
502 (44.5)
165 (14.6)
458 (40.6)
2 (0.2)
503 (44.6)
165 (14.6)
459 (40.7)
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Table 1  Continued.
Variable Categories N (%) N (%) after  
imputation
Hair colour Red
Light blond
Dark blond
Brown/black
91 (8.1)
326 (28.9)
510 (45.3)
200 (17.7)
Skin colour White
White, slightly brown 
Light brown
560 (49.7)
554 (49.2)
13 (1.2)
Tanning ability Tans easily
Does not tan easily
514 (45.6)
613 (54.4)
Eye colour Blue/grey
Green
Brown
Missing
712 (63.2)
193 (17.1)
218 (19.3)
4 (0.4)
714 (63.4)
194 (17.2)
219 (19.4)
Nevus density None
Some
Quite a few
Many
Missing
255 (22.6)
535 (47.5)
232 (20.6)
82 (7.3)
23 (2.0)
260 (23.1)
544 (48.3)
236 (21.0)
87 (7.7)
Freckles on the face None
Some
Quite a few
Many
Missing
491 (43.6)
410 (36.4)
143 (12.7)
43 (3.8)
40 (3.5)
508 (45.1)
420 (37.3)
149 (13.2)
50 (4.4)
Freckles on the arm None
Some
Quite a few
Many
Missing
441 (39.1)
416 (36.9)
170 (15.1)
66 (5.9)
34 (3.0)
454 (40.3)
267 (23.7)
176 (15.6)
70 (6.2)
Living abroad in (sub) 
 tropical country for >1 year
No
Yes
Unknown
1055 (93.6)
56 (5.0)
16 (1.4)
1068 (94.8)
59 (5.2)
Working outside Never or < 1 year
1-10 years
>10 years
Missing
966 (85.7)
82 (7.3)
68 (6.0)
11 (1.0)
972 (86.2)
85 (7.5)
69 (6.1)
Moderate sunburn < 18 Never
1-2 times
3-5 times
≥ 6 times
Unknown
Missing
121 (10.7)
264 (23.4)
235 (20.9)
302 (26.8)
200 (17.7)
5 (0.4)
123 (10.9)
265 (23.5)
235 (20.9)
302 (26.8)
201 (17.8)
Table 1  Continued.
Variable Categories N (%) N (%) after  
imputation
Severe sunburn < 18 Never
1-2 times
3-5 times
≥ 6 times
Unknown
Missing
402 (35.7)
365 (32.4)
118 (10.5)
96 (8.5)
143 (12.7)
3 (0.3)
403 (35.8)
365 (32.4)
118 (10.5)
98 (8.7)
143 (12.7)
Moderate sunburn as adult Never
1-2 times
3-5 times
≥ 6 times
Unknown
Missing
160 (14.2)
429 (38.1)
252 (22.4)
206 (18.3)
76 (6.7)
4 (0.4)
161 (14.3)
430 (38.2)
253 (22.4)
207 (18.4)
76 (6.7)
Severe sunburn as adult Never
1-2 times
3-5 times
≥ 6 times
Unknown
Missing
586 (52.0)
363 (32.2)
77 (6.8)
52 (4.6)
46 (4.1)
3 (0.3)
587 (52.1)
363 (32.2)
78 (6.9)
53 (4.7)
47 (4.2)
Protection measures < 18 Never-rarely
Rarely-sometimes
Sometimes-often
Often-always
Missing
278 (25.5)
451 (40)
210 (18.6)
28 (2.5)
151 (13.4)
295 (26.2)
503 (44.6)
268 (23.8)
61 (5.4)
Protection measures > 18 Never-rarely
Rarely-sometimes
Sometimes-often
Often-always
Missing
96 (8.5)
360 (31.9)
476 (42.2)
105 (9.3)
90 (8.0)
104 (9.2)
390 (34.6)
513 (45.5)
120 (10.6)
Sun bed use Never
Ever
Missing
356 (31.6)
768 (68.1)
3 (0.3)
358 (31.8)
769 (68.2)
Sunny holidays  
(minimally 2 weeks/year)
No
Yes
Unknown
Missing
511 (45.3)
479 (42.5)
98 (8.7)
39 (3.5)
528 (46.9)
496 (44.0)
103 (9.1)
Family history for  
skin cancer
No
Yes
943 (83.7)
184 (16.3)
Abbreviations: SD, standard deviation, SSM, superficial spreading melanoma; NM, nodular melanoma; 
LM(M), lentigo maligna (melanoma).
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Uni- and multivariable analyses
In Table 1, patient- and tumour characteristics are shown based on the observed 
data only and on the imputed data. All subsequent analyses were based on imputed 
data (see Table 2). 
 In the univariable analyses, an older age, a lentigo maligna (melanoma) as first 
melanoma versus superficial spreading melanoma, a high nevus density versus 
none, many freckles on the arm versus none, working outside for more than 10 years 
versus less than 1 year, and ever having a severe sunburn before the age of 18 years 
versus never, significantly increased the risk of developing a second melanoma. 
A melanoma with a Breslow thickness of > 1 mm was associated with a lower risk 
versus in situ melanoma. The same holds for melanoma located on the extremities 
versus the head/neck region, and a green eye colour versus a blue/grey eye colour. 
A light hair colour and having at least one severe sunburn as an adult did not show 
statistically significant associations with the risk of developing a second melanoma, 
but the corresponding p-values were below 0.10 (Table 2). 
In the multivariable analyses, patients who reported to have many nevi had a 5 times 
higher risk compared to patients with none or a few nevi (HR 5.35; 95% CI: 2.20-12.98). 
Patients who had an outside job for more than ten years revealed a two times higher 
risk (HR 2.16; 95% CI: 1.04-4.51) versus an outside job for less than 1 year. Also older 
age at diagnosis of the first melanoma was significantly associated with an elevated 
risk (HR 1.04 per year; 95% CI: 1.01-1.07), while patients with invasive melanoma >1 mm 
had a decreased risk compared to patients with an in situ melanoma (HR 0.40; 95% 
CI: 0.16-0.98). 
Table 2   Uni- and multivariable Cox regression models to estimate risk factors for  
second primary melanoma.
Variable Categories Univariable HR 
(95% CI)
Multivariable HR 
(95%CI)
Gender Male
Female
1.00
0.66 (0.40-1.09)
Age at diagnosis - 1.03 (1.01-1.05 ) 1.04 (1.01-1.07)
Age categories <40 years
40-60 years
≥60 years
1.00
1.32 (0.62-2.79)
1.78 (0.83-3.84)
Melanoma  subtype SSM
NM
LM(M)
Other 
1.00
0.99 (0.35-2.76)
2.11 (1.10-4.02)
0.67 (0.28-1.59)
1.00
1.33 (0.42-4.21)
1.04 (0.33-3.39)
0.50 (0.19-1.30)
Body site Head/neck
Trunk
Extremities
1.00
0.76 (0.40-1.46)
0.43 (0.22-0.85)
1.00
1.21 (0.48-3.07)
0.79 (0.31-2.04)
Tumour ulceration No
Yes
1.00
0.93 (0.36-2.42)
Breslow  
categories
In situ
≤1.00 mm
> 1.00 mm
1.00
0.61 (0.34-1.11)
0.49 (0.24-0.99)
1.00
0.53 (0.24-1.16)
0.40 (0.16-0.98)
Marital status Single
With partner
Other
1.00
0.85(0.44-1.64)
0.00 (0-.)
Education level Low/Intermediate
High
1.00
1.33 (0.79-2.23)
BMI category Normal 
Overweight/Obese
1.00
1.12 (0.67-1.85)
Smoking status None smoker
Ex-smoker
Current smoker
1.00
0.64 (0.27-1.55)
1.06 (0.63-1.80)
Hair colour Red/Light blond
Dark blond/Brown/black
1.00
0.63 (0.38-1.05)
1.00
0.73 (0.43-1.25)
Skin colour White
White, slightly brown 
Light brown
1.00
0.79 (0.48-1.31)
0.00 (0-.)
Tanning ability Tans easily
Does not tan easily
1.00
0.92 (0.59-1.53)
Eye colour Blue/grey
Green
Brown
1.00
0.39 (0.16-0.98)
0.76 (0.39-1.47)
1.00
0.46 (0.18-1.18)
0.85 (0.43-1.70)
84 85
CHAPTER 4 RISK FACTORS FOR SECOND PRIMARY MELANOMA
4
Discussion
In the present study, we found a 5-year cumulative risk of second primary melanoma 
of 3.7%. This in in accordance with a few other studies which reported the 5-year 
cumulative risks of second primary melanoma, ranging from 2 to 4.5 percent [1-3]. 
Due to differences in the completeness of follow-up or geographical regions, the 
cumulative risks vary. 
A high nevus density was the strongest risk factor for a second primary melanoma in 
our study. Other studies reported an increased risk of multiple primary melanoma in 
patients with high (dysplastic) nevus counts [5, 6, 8, 9, 11, 13]. High (dysplastic) nevus 
count is also one of the most important risk factors for developing a first primary 
melanoma [5, 14-16]. It seems logical that risk factors for a first melanoma also 
increase the risk of a second melanoma if they do not change over time. Genetic 
factors are likely to play a role, as many genetic studies have shown that associations 
exist between nevus-genes (IRF4, CDKN2A) and melanoma [17-19]. 
Interestingly, we found that working outside for more than 10 years was a strong risk 
factor for a second primary melanoma. Occupational sun exposure is often thought 
to represent continuous or cumulative sun exposure, rather than intermittent sun 
exposure [20], which is an established risk factor for melanoma in general. For 
cumulative sun exposure, even an inverse association with melanoma has been 
suggested. However, a meta-analysis showed a positive association of cumulative 
sun exposure with melanoma in countries at higher latitudes [21]. In previous studies, 
inconsistent results have been reported on the association of occupational exposure 
to sunlight and developing a first melanoma: it was found not to be associated with 
melanoma in one study [20], while an association with melanoma was shown at lower 
latitudes in another study [22]. As for multiple primary melanoma, an association with 
occupational exposure was previously not found by Kricker et al. [12] who performed 
a study in more than 3000 melanoma patients from different countries (Australia, 
Canada and the USA). They used detailed methods to calculate lifetime occupational 
sun exposure, in contrast to the three questions on working outside in our questionnaire. 
The association we found between working outside and second primary melanoma 
therefore has to be interpreted with care. 
 Nonetheless, compared to most other histological subtypes of melanoma, 
lentigo maligna (LM) and lentigo maligna melanoma (LMM) are reported to be more 
closely associated with cumulative sun exposure. In our study, patients who worked 
outside had a larger proportion of LM(M)s than patients who worked outside for less 
than 1 year, compared to other melanoma subtypes (data not shown). This supports 
the positive association of this melanoma subtype with occupational and thus 
Table 2   Continued.
Variable Categories Univariable HR 
(95% CI)
Multivariable HR 
(95%CI)
Nevus density None-Some
Quite a few
Many
1.00
0.99 (0.50-1.98)
3.15 (1.63-6.07)
1.00
1.64 (0.77-3.52)
5.35 (2.20-13.00)
Freckles on the face None-Some
Quite a few
Many
1.00
1.33 (0.67-2.64)
1.42 (0.45-4.49)
Freckles on the 
arm 
None-Some
Quite a few
Many
1.00
0.95 (0.45-2.01)
2.69 (1.26-5.76)
1.00
0.80 (0.36-1.77)
2.00 (0.88-4.51)
Living abroad in 
(sub) tropical country 
for >1 year
No
Yes
1.00
1.31 (0.46-3.60)
Working outside Never or < 1 year
1-10 years
>10 years
1.00
0.73 (0.23-2.35)
3.21 (1.62-6.36)
1.00
0.64 (0.20-2.12)
2.16 (1.04-4.51)
Moderate sunburn 
< 18 
Never
Ever
Unknown
1.00
1.00 (0.42-2.36)
1.43 (0.55-3.71)
Severe sunburn  
< 18 
Never
Ever
Unknown
1.00
1.68 (0.92-3.07)
1.46 (0.62-3.45)
1.00
1.38 (0.68-2.80)
1.18 (0.41-2.91)
Moderate sunburn 
as adult
Never
Ever 
Unknown
1.00
1.50 (0.65-3.50) 
1.02 (0.25-4.07)
Severe sunburn as 
adult 
Never
Ever 
Unknown
1.00
1.59 (0.95-2.68)
1.47 (0.44-4.88)
1.00
1.32 (0.73-2.42)
1.18 (0.28-5.06)
Protection measures 
< 18 
Never-rarely-sometimes
Often--always
1.00
0.71 (0.39-1.30)
Protection measures 
> 18 
Never- Rarely-Sometimes
Often-always
1.00
1.08 (0.65-1.80)
Sun bed use Never
Ever
1.00
0.78 (0.46-1.32)
Sunny holidays  
(minimally 2 weeks/
year) 
No
Yes
Unknown
1.00
1.31 (0.76-2.26)
1.69 (0.73-3.92)
Family history for  
skin cancer
No
Yes
1.00
1.29 (0.69-2.42)
Abbreviations: HR, hazard ratio; CI, confidence interval; SSM, superficial spreading melanoma; NM, nodular 
melanoma; LM(M), lentigo maligna (melanoma).
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cumulative sun exposure. In addition, we observed more head and neck melanomas 
in patients who have worked outside during a long time period, and LM(M) is typically 
located on sun-damaged skin, especially on the face. 
 In the univariable analyses, both patients with LM(M) and melanomas in the 
head/neck region showed an increased risk of developing a second primary 
melanoma compared to other histological subtypes and locations of the primary 
melanoma. Older age at diagnosis and an in situ melanoma were also statistically 
significant risk factors for second melanomas. Of the in situ melanomas, 72% were 
lentigo maligna. Older age is also associated with a history of cumulative sun 
exposure and LM(M) [23]. In line with our results, Bradford et al. [24] observed that 
patients with melanoma on the head or neck had the highest risk of developing a 
subsequent melanoma. Similarly, Savoia et al. [13] found that patients over 70 years 
old and with a LM(M) as first melanoma were more prone to develop a second 
primary. Siskind et al. also found that having melanoma in situ as a first melanoma 
increased the risk of a second primary melanoma [9].
 Altogether, these findings may indicate that melanoma patients with high 
cumulative sun exposure are at higher risk of second primary melanomas. However, 
sun exposure differs a lot between countries at different latitudes, making it difficult 
to compare cumulative sun exposure in a country like the Netherlands and for 
example, Italy or Australia. Chronic sun exposure in countries at high latitude may 
actually be quite similar to intermittent sun exposure. 
In contrast to other studies, we did not find a significant association between family 
history of skin cancer and second primary melanoma. Family history of melanoma is 
an important risk factor for second primary melanoma as shown in a number of 
studies [5, 6, 8, 9, 25]. This may be related to a genetic predisposition which causes 
first degree relatives to be at higher risk of developing additional melanomas. 
Remarkably, one population-based case-control study found an inverse association 
between family history of melanoma and multiple primary melanoma [11]. In the 
present study, patients were asked to fill out their family history for any type of cancer 
and not specifically for melanoma, and many patients only reported ‘skin cancer’. 
After additional telephone surveys with patients we found out that many patients were 
unable to distinguish between melanoma and non-melanoma skin cancer in their 
first-degree relatives. The fact that non-melanoma skin cancer has a different 
spectrum of genetic risk factors than melanoma [26, 27] might explain why a family 
history of skin cancer in general is not significantly associated with the risk of second 
primary melanoma. 
In the univariable analysis, a high number of freckles on the arm and eye colour were 
also associated with developing multiple melanomas. However, like the effect of anatomic 
location and histological subtype, the association was no longer significant after 
adjustment by other variables. Nevertheless, these factors might assist in recognising 
patients who are at a high risk of developing a subsequent melanoma.
A strength of this study is the availability of many possible risk factors for second 
primary melanoma as well as its population-based character. However, there was a 
lack of power due to the relatively small number of events and the large number of 
risk factors in the Cox regression analyses. 
According to the current Dutch melanoma guideline, patients with a melanoma in situ 
or a melanoma less than 1 mm thick should not be offered routine follow-up [28]. In 
other (European) guidelines, follow-up for patients with in situ melanoma is not 
mentioned [29, 30] or advised against [31]. Since the findings of this and other 
studies suggest that patients with a melanoma in situ are at higher risk of developing 
second primary melanomas, guidelines may have to be adjusted. 
 For patients with a melanoma thicker than 1 mm, the guideline advises a 
maximum follow-up of 5 years. One-third of second melanomas were diagnosed 5 
years after the first, and the risk of developing a second primary remained elevated 
after 5 years. This may be a reason to continue follow-up after 5 years in patients with 
risk factors for second primary melanoma. 
 In conclusion, dermatologists may need to intensify or lengthen follow-up for 
patients with previous in situ melanoma, high cumulative sun exposure and certain 
phenotypic characteristics, such as high nevus density. 
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Abstract
Background
In the transition from the sixth to the seventh edition of the American Joint Committee 
on Cancer (AJCC) melanoma staging system, mitotic activity was incorporated, while 
Clark level of invasion was abandoned.
Objective 
To investigate the effect of this change on the pathological tumour (pT)1 substaging 
of primary cutaneous melanomas and the possible clinical implications.
Methods 
Patients with pT1 melanomas, diagnosed in the period January 2003 to March 2011, 
were selected from a population-based cohort study on cutaneous melanoma in 
the eastern part of the Netherlands. The pT1 melanomas were systematically reviewed 
by an expert pathologist and classified according to both the sixth and the seventh 
editions of the AJCC staging system. The shift of melanomas between pT1 substages, 
classified according to the two staging systems, was determined.
Results 
In total, 260 pT1 melanomas were included. Overall 28% (57/207) of all pT1a melanomas 
shifted to pT1b when classified according to the new seventh staging classification, 
because of the presence of mitoses. Some 32% (17/53) of all pT1b melanomas shifted 
to pT1a. The percentage of pT1b melanomas relative to all pT1 melanomas increased 
from 20% to 36%.
Conclusions 
The addition of mitotic activity to the pathological staging system, according to the 
seventh edition of the AJCC staging system, resulted in a considerable change in the 
classification of thin cutaneous melanomas. This shift has clear clinical implications, 
as it is advised in the Dutch guideline that patients with pT1b melanoma should be 
offered a sentinel lymph node biopsy.
What’s already known about this topic?
• Mitotic rate is an important prognostic factor in thin melanoma and was therefore 
incorporated in the seventh American Joint Committee on Cancer tumour-node- 
metastasis staging system.
What does this study add? 
• The addition of mitotic rate to the melanoma staging system causes a 28% shift 
from pathological tumour (pT)1a to pT1b melanoma and an absolute increase of 
15% of pT1b melanoma.
• This shift has clear clinical implications, as it is advised in the Dutch and British 
guidelines that pT1b melanoma patients should be offered a sentinel lymph node 
biopsy.
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Introduction
In clinical practice there is a continuing need for prognostic factors that can accurately 
predict the risk of progression of thin cutaneous melanomas (Breslow thickness 
≤1 mm). This can aid clinicians in the formulation of adequate follow-up schedules or 
the decision to perform additional diagnostic procedures, such as a sentinel lymph 
node biopsy (SLNB).
In 2009 the tumour-node-metastasis (TNM) staging of melanoma was updated by 
the American Joint Committee on Cancer (AJCC) by adding mitotic rate to the staging 
system, and abandoning Clark level of invasion [1]. The revision was adopted by the 
Union of International Cancer Control. Mitotic rate, defined as the number of dermal 
mitoses per mm2, has proven to be a strong prognostic factor in thin melanoma [1].
In the Netherlands, the scoring of mitotic rate was incorporated in the revision of the 
national melanoma guideline in 2012 [2]. In the current guideline it is advised that 
absence or presence of dermal mitoses in all pT1 melanomas is documented in 
the pathology report. Prior to this revised guideline, mitotic rate was not routinely 
assessed by pathologists in Dutch patients with melanoma; in 2011 the mitotic activity 
was scored in only 16% of all pathological tumour (pT)1 melanomas (source: 
Netherlands Cancer Registry). An increase in the scoring of mitotic rate is likely to 
occur after the implementation of this new guideline. In addition, the new guideline 
advises that an SLNB is offered to all patients with melanoma of stage IB and higher, 
which includes patients with stage pT1b (i.e. melanomas with a Breslow thickness ≤1 
mm and a mitotic rate higher than 1 mitosis per mm2 and/or ulceration). The U.K. 
guideline of 2010 also recommends offering an SLNB to patients with melanoma of 
stage pT1b and higher [3]. In guidelines from other countries it is advised that an 
SLNB be performed only in selected high-risk cases of melanoma of ≤1mm, e.g., with 
ulceration or ≥1 mitoses per mm2, especially in the subgroup of melanomas with a 
Breslow thickness of 0.75-0.99 [4-6]. An SLNB can be a complex procedure that 
carries a risk of complications and the survival benefit of this approach is still unclear 
[7]. The implications of the new staging protocol may thus be quite extensive for both 
patients and clinicians.
We were interested in how many pT1 patients staged according to the former AJCC 
staging system would be staged differently using the seventh edition of the AJCC 
staging system, and how many extra SLNBs would then have to be performed.
Patients and methods
Patients
This study was part of an ongoing population-based study on the association of genetic 
variants and lifestyle-related risk factors with the risk and prognosis of melanoma. In total, 
1,278 patients with primary melanoma from the eastern part of the Netherlands were 
recruited via the Netherlands Cancer Registry held by Comprehensive Cancer Centre 
the Netherlands. This is a nation-wide database in which data on all newly diagnosed 
patients with cancer in the Netherlands are recorded. All patients were diagnosed 
with melanoma in the period 2003-11. Participation in the study included the donation 
of a blood sample and completion of a questionnaire on general health items and 
melanoma risk factors.
Pathology review
Of the 1,278 patients, a random sample of 540 melanomas diagnosed in the three 
largest pathology laboratories in the eastern region of the Netherlands (the Radboud 
University Medical Centre in Nijmegen, the Canisius Wilhelmina Hospital in Nijmegen, and 
the Rijnstate Hospital in Arnhem) was reviewed by the same pathologist, experienced in 
melanocytic tumours (W.A.M.B). From both the Radboud University Medical Centre 
and the Canisius Wilhelmina Hospital, all available melanomas were reviewed. From 
the Rijnstate Hospital in Arnhem a random sample of 13% (n=90) melanomas was 
reviewed due to manpower constraints. 
 In the review a diagnosis was rendered, and prognostic factors such as Breslow 
thickness, mitotic activity, Clark level, ulceration, microsatellites and regression, and 
other features such as tumour- infiltrating lymphocytes and presence of  pre-existent 
nevi were scored.
Analyses
Of the 540 reviewed lesions, all 276 pT1 tumours were selected. With the extra 
information that was acquired by the review, these pT1 tumours were classified twice, once 
by the ‘old’ sixth and once by the ‘new’ seventh staging system of the AJCC. A contingency 
table was created to determine the shift of melanomas classified as pT1a by the old 
protocol to pT1b sub-stage by the new protocol, as well as the shift of patients 
classified as pT1b by the old protocol to pT1a by the new protocol. Furthermore, the 
increase of pT1b tumours relative to all pT1 tumours was calculated.
All statistical analyses were performed with SPSS 20.0 software (IBM Corp., Chicago, 
USA).
98 99
CHAPTER 5 IMPACT OF MITOTIC ACTIVITY ON THE PATHOLOGICAL SUBSTAGING OF PT1 MELANOMA
5
Results
In total, 276 pT1 melanomas were reviewed, which were diagnosed in 274 patients. As 
relevant information on mitotic rate, Clark level and/or ulceration was missing in 16 
melanomas, due to impaired quality of the pathology slides or incomplete inclusion 
of the melanoma in pathology blocks, these 16 melanoma’s were excluded from all 
analyses. Eventually, 260 melanomas, diagnosed in 258 patients, were included in 
the analysis.
Patient and tumour characteristics are shown in Table 1. The shift between the pT1 
substages when classified by the sixth or the seventh AJCC staging system was 
calculated by creating a contingency table, shown in Table 2. In total, 57 / 207 tumours 
(28%) that were staged as pT1a according to the sixth classification, shifted to pT1b 
when staged according to the seventh classification. Seventeen out of 53 pT1b 
tumours (32%) shifted to pT1a. Thirty-six out of 53 tumours (67.9%) remained in stage 
pT1b, and in 32 cases this was determined only by Clark level or mitotic activity, as 
ulceration was absent or not assessable in these cases. The percentage of pT1b 
tumours relative to all pT1 tumours included in the study increased from 20.4% (53 / 
260) to 35.8% (93 / 60), an increase of 15%.
Discussion
The importance of tumour mitotic rate in melanoma was first mentioned by Allen and 
Spitz in 1953 [8] and has since been studied frequently. In the 1970s it became clear 
that mitotic rate represents an important prognostic factor in thin melanoma [9]. 
However, it was only in 2009  the AJCC considered the evidence strong enough to 
incorporate this item in the TNM staging system [1].
In the current study, we showed that a substantial shift of patients between substages 
pT1a and pT1b occurs by adding mitotic rate to the staging system. The clinical 
implication of this shift between pT1 substages is that more patients are predicted to 
have a worse prognosis and should therefore be offered a sentinel node procedure 
to be more accurately informed about their prognosis, as is advised in the latest 
Dutch and British guidelines.
Compared with the previous guideline by which only patients with pT2 and higher 
would be offered SLNBs, pT1b patients would also be offered a SLNB with the 2012 
guideline fully implemented. An increase of 15% in pT1b melanomas as a result of the 
modification of the staging system would lead to a significant increase in the yearly 
workload of surgeons, apart from the still increasing incidence of melanoma.
Table 1   Patient and tumour characteristics of 260 pT1 melanomas, diagnosed in  
258 patients.
n % 
Mean age at diagnosis, years (SD) 50.9 (12.0)
Gender Male 
Female 
95
163
36.8
63.2
Melanoma subtype SSM
NM
LMM
ALM
Other/unknown
245
2
3
3
7
94.2
0.8
1.2
1.2
2.7
Clark level 
 
II 
III 
IV 
161
49
50
61.9
18.8
19.2
Ulceration 
 
Yes 
No 
Unknown/NA
4
253
3
1.5
97.3
1.2
Mitotic activity Yes 
No 
91
169
35.0
65.0
Abbreviations: SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna 
melanoma; ALM, acrolentiginous melanoma; NA, not available.
Table 2   Pathological tumour (pT)1 stages of revised tumours according to the sixth  
and seventh editions of the American Joint Committee on Cancer melanoma 
staging system.
Seventh edition
Sixth  
edition 
pT1a pT1b Total 
pT1a 150 
72.5%
57 
27.5%
207
100%
pT1b 17
32.1%
36
67.9%
53
100%
Total 167
64.2%
93
35.8%
260
100%
Percentages are of row totals.
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However, the evidence for the benefit of a SLNB in pT1b melanoma patients is still 
limited. Sekula-Gibbs and Shearer performed a literature review on this advice [10]. 
Their overall conclusion was that the advice should apply to all patients with ≥1 
mitoses per mm2 because mitotic rate has been associated with a positive SLNB in 
patients with both thin and thicker melanoma in a number of reports [11-15]. A few 
studies that performed multivariable regression analysis in order to identify risk factors 
for a positive SLNB, did not find an association of mitotic rate > 1 per mm2 with a 
positive SLNB [16, 17].
Studies that investigated SLNB procedures in thin melanoma found a positive SLNB 
rate ranging from 2.9% to 7% [12, 13, 15-21]. Besides mitotic rate, other factors 
associated with a positive SLNB in thin melanoma were young age [12, 18, 21], male 
gender [11, 12], Breslow thickness [12], ulceration, vertical growth phase, and a low 
rate of tumour infiltrating lymphocytes [11]. Most study populations were small and 
might have represented only a selection of patients. For example, patients may have 
asked their doctors for an SLNB, or patients may have had other unfavourable char-
acteristics that demanded an SLNB, which were not reported or unknown. We have 
to be careful with extrapolating the findings of these studies to all thin melanomas.
It is unclear whether the burden and costs of a sentinel node procedure in thin 
melanomas weigh up against the benefits. SLNBs do give more information about 
the prognosis of patients with thin melanoma [15, 18, 20, 21], but it is unclear whether 
disease-free or overall survival is improved by the procedure. Results of the currently 
ongoing Multicenter Selective Lymphadenectomy Trial II will ideally reveal this. In this 
study, we were able to include a large series of patients with melanoma, and to 
perform a review of pT1 tumours by an expert pathologist with extensive expertise in 
melanoma. It would have been interesting to study the effect of the shift from pT1a to 
pT1b in terms of progression-free or overall survival. Although we had follow-up data 
for the majority of patients and the median follow-up of patients was 5.5 years, there 
were too few events to make comparisons between the stage groups according to 
the sixth and seventh AJCC staging systems. For valid comparisons we would need 
a longer follow-up and a larger patient series. 
In conclusion, we have shown that the new seventh AJCC TNM staging system 
causes a shift in pT1 melanoma, which may lead to an increase in the number of 
patients with an indication for SLNB. To clarify the value of SLNBs in thin melanoma, 
it would be interesting to perform a large prospective study in which patients with 
pT1 melanoma and certain relatively unfavourable pathologic features (i.e. Breslow 
0.75-1.00 mm, ulceration, positive mitotic rate) are randomised into SLNB versus 
watchful waiting and followed for a long (i.e. >10 year) period.
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Abstract
Background
The Dutch melanoma guideline advises to examine one central block of the 
re-excision scar in case of a complete primary excision. To increase the evidence for 
this recommendation, we re-evaluated how often residual melanoma was found in 
re-excision specimens of a large series of completely excised melanomas.
Methods
Of 1,209 Dutch melanoma cases, pathology reports of primary excisions were 
reviewed. Presence of melanoma in the margins was scored. All melanomas with a 
complete primary excision were included and pathology reports of re-excisions were 
reviewed. Presence of residual melanoma in the re-excision specimen and the 
number of blocks were scored. Slides of re-excision specimens containing residual 
melanoma were reviewed.
Results
Eventually, in four out of 812 melanomas (0.5 %) with a complete primary excision, 
residual melanoma was found in the re-excision specimen. The free margins of the 
primary melanomas in these cases ranged from 0.5–3.5 mm. In one case, the margin 
for melanoma in situ was 0.2 mm. 
Conclusions
In <1 % of initially completely excised melanomas, residual melanoma was found in 
the re-excision specimen. Histopathological examination of these re-excision specimens 
may not be cost-efficient. Our findings even imply that a re-excision could safely be 
omitted in selected cases of completely excised melanomas.
Introduction
 
Cutaneous melanoma is among the most aggressive forms of skin cancer. Perhaps, 
the most crucial part of melanoma treatment nowadays is a wide local (re-)excision 
of the primary melanoma. The rationale for performing a wide local excision is 
twofold: first, a field effect may have taken place in the area around the primary 
melanoma causing the skin to be more prone to second primary tumours; and 
second, microsatellites can occur around the melanoma [1, 2]. Both are targeted 
with a wide re-excision. The margins of the excision have been much debated, and a 
number of randomised trials have elicited that the margin of the excision should 
depend on the Breslow thickness and should never exceed 2 cm [3-6].
In current clinical practice, the advice is to first perform a diagnostic excision with a 
2-mm margin of every melanocytic lesion with a suspicion of melanoma and assess 
these lesions histopathologically [7]. If a melanoma diagnosis is confirmed, a wide 
re-excision is advised as part of the further management. Direct wide excision is not 
advised, as suspicious lesions are often benign and would then receive unnecessary 
wide excisions. In addition, the Breslow thickness and presence or absence of 
prognostic parameters (ulceration, dermal mitoses) determine whether a sentinel 
node procedure is indicated, which is optimally performed simultaneously with the 
re-excision. 
All re-excision specimens are examined histopathologically, and until 2005, no clear 
guideline advice existed as to what extent these should be assessed, in particular 
when the primary excision was complete. A large part of the pathologist’s time is 
spent on examination of these specimens, while the benefit of this procedure - in 
terms of prevention of recurrence - is not completely clarified. 
In 2005, the Dutch guideline recommended, after complete excision, histological 
examination of three central blocks of the scar, based on one of three studies on 
re-excision samples of melanoma that were performed in the UK [8]. These few 
studies have shown that residual melanoma is rarely found in the re-excision when 
the diagnostic excision was complete [8-10]. The latest Dutch melanoma guideline 
(revised in 2012) further adjusted the protocol for the handling of re-excisions based 
on these studies. It now recommends examining only one central block of the 
re-excision in case of complete excision and absence of macroscopic abnormalities 
in the re-excision specimen. To the best of our knowledge, no other (inter)national 
guidelines give recommendations for the handling of melanoma re-excision 
specimens [11-14]. 
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To investigate the benefit of the histopathological examination of re-excision specimens 
and to help formulate better guidelines with respect to re-excision sample handling, 
we performed a study in a large series of melanoma patients. We assessed the 
percentage of cases with residual melanoma in the re-excision specimen, after a 
complete primary excision. 
Materials and methods
Study population
The present study was part of an ongoing population-based study on the association 
of genetic variants and lifestyle-related risk factors with the risk and prognosis of 
melanoma. For this study, 1263 melanoma patients from the Eastern part of the 
Netherlands were recruited through the Netherlands Cancer Registry (NCR). In the 
NCR, data is recorded from all newly diagnosed cancers in the Netherlands since 
1989. All patients were diagnosed with cutaneous melanoma between January 2003 
and April 2011. Participation in the study included the donation of a blood sample 
and completion of a questionnaire on general health items and melanoma risk 
factors. Patients gave informed consent for data retrieval from their medical files. For 
practical reasons, in the present study, we only included melanomas that were 
previously histopathologically handled in one of the three largest pathology laboratories 
in the Eastern part of the Netherlands (i.e. Radboud university medical center, 
Canisius Wilhelmina Hospital and Rijnstate Hospital). Of these 1,209 melanomas, 
pathology reports of the primary excision were extracted from the PALGA database 
(the nationwide network and registry of histopathology and cytopathology in the 
Netherlands). 
Review of pathology reports
All 1,209 reports were reviewed. All melanomas diagnosed after an incision biopsy, 
shave biopsy or excochleation and/or incomplete primary excision were excluded. 
Concerning the remaining melanomas, a search was performed in the PALGA database 
for reports on the wide local re-excision. From these reports the presence of residual 
melanoma and the number of investigated blocks of the re-excision specimens were 
scored. We calculated the percentage of cases with residual melanoma found in the 
re-excision after complete primary excision. 
Histopathological review
From all cases with residual melanoma in the re-excision specimen, the original 
reports of the primary excision were retrieved from the pathology laboratory archives, 
and a histopathological review of possible factors predicting presence of residual 
melanoma (Breslow thickness, ulceration, mitotic rate, microsatellites, regression, 
 tumour-infiltrating lymphocytes, and narrowness of excision) was performed. 
To confirm the presence of residual melanoma, assess the completeness of the 
re-excision and assess the type of residual melanoma (microsatellites, a remnant of 
a previous melanoma or a new melanoma), the slides of the re-excisions with residual 
melanoma were retrieved and reviewed as well. No additional immunostaining 
or immunohistochemistry was performed during the histological review of the 
re-excisions. Furthermore, information on the clinical course of these cases was 
collected. 
Number of blocks
Based on the reports of re-excision specimens, we scored the number of blocks that 
were examined in each case. We calculated the average number of blocks that was 
examined per case per year. 
The statistical analyses were performed with SPSS 20.0 software (IBM Corp., 
Chicago, USA).
Results
In- and exclusion of cases
Out of 1,209 melanoma cases, 313 cases were excluded because of (i) an incomplete 
primary excision (235 cases),(ii) lack of data on completeness of the excision (61 
cases), and (iii) a punch, shave or excochleation biopsy rather than a diagnostic 
excision (144 cases), or a combination of these exclusion criteria.
Data on the re-excision was not traceable in the PALGA database for 96 cases. After 
reviewing the clinical files of these 96 cases, we found that in 67 of these cases, no 
re-excision was performed. In 15 cases, however, a re-excision was performed, of 
which 12 had no residual melanoma in the re-excision. In the other three cases, this 
was unknown. In 14 cases, no clinical data was available. In total, 84 cases were 
excluded because no re-excision was performed or information on the re-excision 
was lacking. Eventually, 812 cases were included in the analysis. In Table 1, patient 
and tumour characteristics are shown of the included cases versus the total study 
population. Included cases were on average 1.5 years younger, were more likely to 
have had a superficial spreading melanoma, a low pT1 stage (pT1 or pT2), and less 
likely to have had an in situ melanoma, lentigo maligna, ulceration or a melanoma 
located in the head and neck area, compared with the total study population.
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Cases with residual melanoma cells in the re-excision specimen
Review of the reports of re-excision specimens of these 812 cases revealed six cases 
(0.7%) with residual melanoma. The original histology reports and slides of these six 
cases were reviewed. See Table 2 for clinical and pathological characteristics of 
these six cases. In two cases the primary excision was incomplete for melanoma in 
situ (Mis). In two additional cases, margins were very narrow for Mis, 0.2 and 1 mm, 
respectively. In four out of six cases the primary excision was very narrow for the 
invasive melanoma (ranging from 0.5 to 2 mm). The primary excisions showed deep 
mitoses in three of the cases, and in four of the cases tumour infiltrating lymphocytes 
were seen. The applicable Breslow thickness varied from 0.65 to 3.8 mm. In the 
re-excision specimens, four cases had a rest of the previously found melanoma, and 
two cases showed a non-invasive lesion (i.e. one melanoma in situ and one lentigo 
maligna). In none of the cases, satellites were present in either the primary or 
re-excision specimen.
Number of blocks
The average number of investigated blocks decreased from 10 (95% confidence 
interval 9–11) in 2003, to 4 (95% CI 3–5) in 2010 (see Fig. 1).
Table 1   Patient and tumour characteristics of included cases versus the total study 
population
Included 
 melanoma cases 
(n=812)
Total study 
population
(n=1,209)
P value a
Age at diagnosis 
(mean, ±SD)
50.9 (12.9) 52.4 (12.3) 0.016
N (%) N (%)
Tumour subtype SSM
NM
LMM
ALM
LM
Mis 
Other/unknown
569 (70.1)
57 (7.0)
9 (1.1)
2 (0.2)
7 (0.9)
109 (13.4)
59 (2.3)
745 (61.6)
82 (6.8)
31 (2.6)
8 (0.7)
92 (7.6)
157 (13.0)
94 (7.8)
<0.001
Tumour site Trunk/back
Head/neck
Limbs
Other/unknown
293 (36.1)
61 (7.5)
423 (52.1)
35 (4.3)
387 (32.0)
181 (15.0)
591 (48.9)
50 (4.1)
<0.001
Breslow thick-
ness b 
In situ
≤1.0 mm
1.01-2.0 mm
2.01-4.0 mm
>4.0 mm
NA
85 (10.5)
440 (54.2)
166 (20.4)
60 (7.4)
12 (1.5)
49 (6.0)
212 (17.5)
591 (48.9)
225 (18.6)
79 (6.5)
23 (1.9)
79 (6.5)
<0.001
Ulceration Yes
No
Unknown
34 (4.2)
566 (69.7)
212 (26.1)
62 (5.1)
744 (61.5)
403 (33.3)
0.001
Mitotic activity Yes
No
Unknown
144 (17.7)
366 (45.1)
302 (37.2)
192 (15.9)
514 (42.5)
503 (41.6)
0.14
Abbreviations: SD standard deviation, SSM superficial spreading melanoma, NM nodular melanoma, 
LMM lentigo maligna melanoma, ALM acrolentiginous melanoma, LM lentigo maligna, Mis melanoma in 
situ, NA not available.
a   P values derived from independent-samples t test (age) or Pearson chi-square tests (other variables).
b   Categories according to pathological tumour (pT) stages defined by the American Joint Committee on 
Cancer in 2009.
Figure 1  Mean number of examined blocks of the re-excision specimen per year of diagnosis, 
with error bars indicating the 95% confidence interval.
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Table 2   Patient and tumour characteristics of six cases with melanoma cells in the re-excision  
specimen after a complete primary excision.
Patient and  
tumour characteristics
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Year of diagnosis 2003 2007 2007 2008 2009 2009
Gender F M M M F F
Age at diagnosis 68 71 63 61 40 49
Localisation Upper arm Lower arm Ear Foot Lower leg Cheekbone
Primary excision
Tumour-free margin 1 mm 2 mm
(Not free for Mis)
3 mm 
(Uncertain for Mis)
0.5 mm
(0.2 mm for Mis)
3.5 mm 
(1 mm for Mis)
2 mm
Breslow thickness 3.8 mm 1.5 mm NA 2.1 mm 0.65 mm  0.85 mm
Melanoma type Superficial spreading 
 melanoma
Superficial spreading 
 melanoma
Lentigo maligna Acrolentiginous  
melanoma
Superficial spreading 
 melanoma
Superficial spreading 
 melanoma
Mitoses ≥ 1 mm + + NA + - -
Ulceration + - - - - -
Satellites - - - - - -
Regression - - - - - -
Tumour-infiltrating lymphocytes + + NA - + +
Re-excision
Melanoma cell type in re-excision Melanoma in situ Primary melanoma  
and melanoma in situ
Primary melanoma Primary melanoma Melanoma in situ Lentigo maligna
Tumour-free margin 8 mm 0.95 mm
0 mm for Mis
0.1 mm 0 mm
(Not free for SSM)
5mm 0 mm
(Not free for lentigo 
 maligna)
Number of blocks 29 6 8 7 19 7
Clinical course
Time (years) from diagnosis to 
first event or last visit 
NAv 5.9 5.6 2.8 3.3 4.1
Eventsb NAv - - Local recurrence
In-transit metastasis
- -
Abbreviations: F female, M male, Mis melanoma in situ, NA not applicable, NAv not available.
a   A second re-excision was performed in these cases. bEvents were defined as local recurrence,  
any form of metastasis, or death.
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Discussion
Already in 1857, William Norris advocated wide excisions of melanoma to prevent 
recurrence [15]. Handley reported the lymphatic permeation of melanoma cells 
around a lymph node metastasis and indicated the need for a wide excision for every 
melanoma [16]. Wong first described abnormalities in melanocytes surrounding 
primary cutaneous melanoma in 1970 [17]. However, only in the early 1980s, wide 
local excisions were fully incorporated in melanoma management.
In the present study, we found that in 0.5% of cases, residual melanoma was detected 
in re-excision specimens of melanomas after a complete primary excision. This 
finding is consistent with the few reports that have been published so far. Martin et al. 
performed a retrospective audit of the handling of melanoma re-excision specimens 
in two histopathology departments and found that in four out of 167 (2.4%) primary 
completely excised cases, residual melanoma was present in the re-excision 
specimens [8]. Johnsson and Sviland did a similar retrospective study and found that 
of 109 wide excisions of melanoma patients, eight had residual melanoma, of which 
six had an incomplete primary excision and two had a macroscopic abnormality in 
the wide excision specimen (i.e. a pigmented area) [10]. Hence, none of the 
specimens with a complete primary excision contained residual melanoma cells. In 
2008, McGoldrick et al. found that in none of the 1007 initially completely excised 
cases residual melanoma was found [9].
In our review of the reports and pathology slides of the cases with residual melanoma 
in the re-excision, we found that in four out of six cases, the primary melanoma was 
excised very narrowly; in two cases, the margins were not free for Mis. Since primary 
excisions for skin tumours, including melanoma, are examined with a bread loaf 
technique, which means that blocks of 4-5 mm are examined, melanoma in the 
margin can be missed in the primary excision [18]. This can lead to residual melanoma 
in the re-excision specimens, especially in case of narrow margins. These four cases 
all had rests of the previously diagnosed invasive melanoma in the re-excision 
specimens. The two remaining cases showed non-invasive lesions: one lentigo 
maligna and one melanoma in situ. The time between excision and re-excision of 
these two cases was 14 and 31 days: it is therefore most likely that these in situ 
lesions were already present at the time of the primary excision, but were not 
recognised as such or not sampled and examined due to bread loafing of the excision 
(bread loafing leads to only partial examination of margins) [18]. There was wide 
variation in the number of examined blocks per re-excision specimen. Two of these 
cases were completely reviewed in 19 and 29 blocks. It is possible that with 
investigating this many blocks, the chance of finding residual tumour cells was higher. 
The other four cases were reviewed in six to eight blocks, in accordance with the 
average number of blocks viewed in the year of excision.
The included cases, when compared with the total study population, were younger, 
less likely to have a lentigo maligna or a melanoma located on the head or neck. This 
could be explained by the fact that we excluded incompletely excised tumours and 
incision or punch biopsies. Lentigo maligna is hard to distinguish from a benign 
lentigo solaris and is often a large lesion on the head and neck area. This is why 
punch biopsies are often applied. In addition, lentigo maligna is hard to delineate 
clinically, thus more often excised incompletely. Also, lentigo maligna patients are 
often older. The included cases were also less likely to have ulceration. However, 
many data were missing on this feature; therefore, this difference must be interpreted 
with caution. Since we aimed our study design at re-excisions of completely excised 
melanomas and not all melanomas, these differences do not change our conclusions.
The median follow-up of the 812 melanoma patients was 4.4 years. One patient with 
acrolentiginous melanoma (ALM) developed a local recurrence after 2.8 years and 
in-transit metastases after 3.7 years. In the re-excision specimen of this case, 
melanoma cells were still present in the margins, and the patient received an 
additional re-excision, which was tumour free. ALM can have a lentiginous in situ 
component that can be difficult to delineate. It must also be noted that this patient 
already had regionally spread disease (a micrometastasis in the sentinel lymph node) 
at the time of diagnosis. Four other cases had no events, and for one case, follow-up 
data was unavailable. Although we have to be careful drawing conclusions, it is likely 
that the presence of tumour cells in the re-excision in this patient had a minor influence 
on the prognosis, if all residual cells were completely removed.
The average number of blocks per case decreased significantly over time. The Dutch 
melanoma guidelines of 1985, 1990 and 1997 gave no recommendations regarding 
the number of blocks that needs to be taken out of re-excision specimens [19-21]. 
The Dutch melanoma guideline of 2005 advised for the first time to take three central 
cuts from the scar of the excision, but only if the primary excision was complete, the 
re-excision specimen was macroscopically normal, and upon histological examination, 
no melanoma remnant was found [22]. We observed a decrease in the average 
number of blocks after 2005, which can be explained by the implementation of the 
2005 guideline. The renewed guideline of 2012 advises to examine only one block of 
the re-excision specimen, but, again, only if the primary excision was complete, the 
re-excision specimen was macroscopically normal, and upon histological examination, 
no melanoma remnant was found [7]. We expect to see a further decline in the average 
number of blocks evaluated in the upcoming years.
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Contrary to the previous single centre studies, we were able to include a relatively 
large, unselected population-based patient series, approached via the Netherlands 
Cancer Registry (NCR). The NCR has nationwide coverage of all new cancer 
diagnoses [23].
Of the 67 cases who received no re-excision, 15 cases were lentigo malignas. Since 
lentigo maligna is an in situ variant of melanoma, it should be re-excised with a 5-mm 
margin according to the Dutch guideline. It is possible that clinicians performing the 
excision decide to take wide margins, in which these cases receive a therapeutical 
excision immediately. On the other hand, lentigo maligna often has a large diameter 
or is located on the face, and taking wide margins is often not feasible, cosmetically 
or functionally. Unfortunately, we had limited information on clinical margins applied 
during the excision of these cases. We do know that in >75% of the complete study 
population the margins standards of the Dutch melanoma guideline were applied 
(0.5 cm for in situ melanoma, 1 cm for melanomas ≤2 mm and 2 cm for melanomas 
>2 mm).
Our findings may be explained in two ways, with different implications. First, the 
findings may be real in the sense that very few re-excisions contain residual tumour, 
especially when the margins of the primary resection were sufficiently wide. In that 
case, it may be argued whether (some of the) re-excisions should be performed. 
Alternatively, re-excisions do contain residual tumour quite frequently, the exact 
reason why re-excisions are performed, but this goes unnoticed because re-excision 
specimens are examined less extensively (with an average of 4-5 blocks) than 
primary excision specimens. If this were the case, omitting the re-excisions would be 
unwise. However, the examination by the pathologist of the re-excision specimen is 
then of no additional benefit to the treatment. Only a prospective study in which every 
re-excision is meticulously investigated will give certainty about the number of cases 
with residual tumour cells. It seems plausible, however, that even in such a setting, 
this number will be extremely low. In addition, previous studies showed no relation 
between the number of blocks and the occurrence of residual tumour in re-excisions 
[8, 10].
With the rising incidence of melanoma, histopathological examination of wide 
re-excisions will be an increasing part of the workload in histopathology departments. 
With the results of this and earlier studies, we conclude that pathological assessment 
of these specimens is not necessary. Omitting the histopathological examination of 
these specimens will save costs and time. Even more, our data imply that a re-excision 
is a redundant procedure in selected cases and may be omitted in thin melanomas 
(i.e. ≤ 1 mm) with completely excised melanomas with sufficiently wide histological 
margins, of at least 2 mm. Thin melanomas occur more frequently nowadays [24] , 
have a low prevalence of microsatellites [2] and a low risk of local skin recurrence 
[25]. Especially in these cases, omitting re-excisions is probably safe and prevents 
many unnecessary and mutilating wide local re-excisions.
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With the studies described in this thesis, we aimed to obtain more insight in epidemio-
logical and clinical aspects of cutaneous melanoma. The main conclusions of the 
studies were: 
(1) The survival of patients with melanoma of unknown primary (MUP) is similar to 
that of patients with melanoma of known primary (MKP) when the metastatic site 
is taken into account. With this knowledge, clinicians can offer adequate 
treatment to patients with MUP and better inform them about their prognosis 
(Chapter 2). 
(2) The reproducibility of a questionnaire on melanoma risk factors was found to be 
fair-to-substantial, depending on the type of question. Questionnaires remain 
useful measurement tools in melanoma research, as they have reasonable re-
producibility and are still the most feasible way to measure melanoma risk factors 
(Chapter 3). 
(3) High nevus density, a long-term job outside, older age, and a melanoma in situ 
as a first primary were found to be risk factors for a second primary melanoma. 
Thus, in addition to phenotypic characteristics, factors related to (cumulative) 
sun exposure appear to be important in the development of second primary 
melanomas. Clinicians should take this into account during follow-up of melanoma 
patients (Chapter 4). 
(4) The addition of mitotic rate to the staging protocol caused a shift of melanomas 
from pT1a to pT1b and an absolute increase in pT1b melanomas. This has clinical 
implications, since the number of patients who are indicated to receive a sentinel 
lymph node biopsy might increase (Chapter 5). 
(5) Only 0.5% of re-excision specimens of completely excised melanoma contained 
residual melanoma cells and no relation with the number of investigated blocks 
could be demonstrated. We therefore conclude that the histopathological examination 
of these re-excision specimens can be omitted. Our findings even imply that a 
re-excision could safely be omitted in selected cases of completely excised 
melanomas (Chapter 6). 
In this chapter I will reflect on the methodology and clinical implications related to 
the results of our studies. In addition, I will discuss future perspectives on melanoma 
research. 
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Questionnaires on melanoma risk factors remain useful 
measurement tools in melanoma research, since an adequate 
biomarker for intermittent sun exposure has yet to be found
The reproducibility of a questionnaire on melanoma risk factors was found to be 
fair-to-substantial and highest for questions regarding phenotypic characteristics. 
For assessing the quality of a questionnaire, both the validity and the reproducibility of 
questionnaire items are important. The validity or accuracy is challenging to investigate, 
as for some questions it is difficult to assess the ‘true’ answer (for example, the number of 
sunburns during childhood). The reproducibility of a question can be assessed quite 
easily by asking the question again after a few weeks. A good reproducibility does 
not guarantee a good validity and vice versa. However, the quantitative estimation of 
the effect of a risk factor will be biased both with imperfect validity and imperfect 
 reproducibility. 
 In our study, the questionnaire items on past sun exposure had a moderate 
 reproducibility and therefore, misclassification likely has occurred. Assessment of a 
biomarker that objectively measures the amount of UV radiation that a person has 
been exposed to would be a valuable addition to information obtained by 
questionnaires. For example, the presence of histologic solar elastosis in skin has 
shown to be associated with lifetime sun exposure [1]. The accumulation of elastotic 
fibers in the upper and middle dermis may be related to activation of the human 
elastin promoter by UV radiation [2] or elastin degradation due to UVB exposure [3]. 
Damage to mitochondrial DNA (mtDNA) has shown to be a good biomarker for 
cumulative UV exposure as well [4, 5]. The advantage of assessing damage in mtDNA 
in sun exposed skin as biomarker rather than in nuclear DNA, is that cells are able to 
accumulate mutations without compromising cell function [4, 6].  
 A disadvantage of these biomarkers is that they do not distinguish between 
intermittent and cumulative sun exposure, which makes them less useful to validly 
assess the type of sun exposure associated with melanoma. Questionnaires – 
provided that they are of good quality - therefore remain valuable measurement tools 
in melanoma research.
 As for daily clinical practice, the value of this type of questionnaires is limited, 
because they are designed for research purposes specifically. However, melanoma 
patients are often asked for information about melanoma risk factors, to assess their 
risk for additional primary melanomas. Also in this setting it is important to know 
which answers have a good reproducibility and which do not. In our study, for example, 
the questionnaire item on the use of sun beds was highly reproducible, and this 
information is probably equally reliable when asked from a patient during consultation.
Changes in tumour classification systems can have a direct impact 
on clinical practice
In Chapter 5 we demonstrated that a considerable shift from pT1a to pT1b melanomas 
occurred with the addition of mitotic rate to the substaging of pT1 melanomas and 
that the absolute number of pT1b increased by 15%. A clinical implication of these 
findings is that more patients should be offered a sentinel lymph node biopsy (SLNB), 
because the most recent Dutch guideline advises to offer this staging procedure to 
all patients with stage 1B melanomas [7]. This implies that the number of patients 
with an indication for a SLNB (i.e., all patients with a stage IB melanoma or higher) 
increases with 1.4% (based on melanoma incidence as reported by the Netherlands 
Cancer Registry in the year 20111). 
 On the other hand, the benefit of a SLNB in terms of overall survival is still unclear 
[8, 9], especially in patients with a thin melanoma [10-14]. Some Dutch surgeons are 
still hesitant to perform this procedure in melanoma patients with a stage IB melanoma, 
both because of the complexity and the questionable benefit of the procedure [15]. 
We expect therefore that the real increase in the number of SLNBs will be lower. 
 Clinicians should be aware that tumor-node-metastasis (TNM) systems are 
updated every five years and that changes in these systems can have a direct impact 
on health care, because diagnostic procedures and subsequent therapeutic choices 
might change for certain patients. 
The Will Rogers phenomenon is a statistical paradox that should be 
taken into account when evaluating updated TNM classifications
To evaluate the accuracy of a new staging system, the overall or disease-free survival 
in staging subgroups is often compared. In our study described in Chapter 5 we 
intended to assess the survival in pT1a and pT1b patients according to two different 
edition of the TNM staging system. Unfortunately, in our study, the number of patients 
and the duration of follow-up was insufficient to make valid comparisons. 
 The publication in which the sixth edition of the TNM staging system was 
presented, reported a 10-year overall survival of 88% for pT1a and 83% for pT1b [16]. 
In the seventh edition, the 10-year overall survival rate was 95% for pT1a and 88% for 
pT1b [17]. The new system appeared to have a better discriminative value, and pT1 
patients seemed to have a better 10-year survival. However, since patient groups 
were from different periods, improved survival rates in subgroups might be artificial. 
1 In 2011, the number of melanoma patients with stage IB or higher was 2550 and the number of stage 
IB melanomas was 231. An increase of 15% in IB melanomas would mean an absolute increase of 
0.15*231=35. Thus the increase of patients with an indication for a SLNB would be (35/2550)*100=1.4%.
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When low stage patients are staged in a worse (higher) stage group with a new 
classification system, the low stage group may get a better prognosis because the 
worst patients are removed from this group. Subsequently, the higher stage group 
may get a better prognosis, because patients with a relatively good prognosis are 
added to the group. Overall, however, the prognosis in the total group of patients 
remains the same. This is called the Will Rogers phenomenon [18]. Since the survival 
of both pT1a and pT1b patients is improved following the latest staging system, this is 
a possibility. Another explanation for the improved survival according to a new 
staging system might be because of ‘zero-time shift’ or lead time bias. As mitotic rate 
is assessed at the same time as Clark level used to be (i.e., during histopathological 
evaluation), it is not likely that this has occurred. Clinicians should be aware that by 
updating TNM staging systems, the survival rates of patients in a certain stage can 
get seemingly better or worse, while the prognosis of the individual patient does not 
change. 
The histopathological examination of re-excision specimens of 
completely excised melanomas is a redundant procedure
In Chapter 6, we described that residual melanoma cells are very rarely present in 
re-excision specimens of completely excised melanomas. In the recent Dutch 
melanoma guideline it is advised to take only one central block in case of a complete 
primary excision, which was partly based on three studies from the UK [19-21]. These 
studies showed that residual melanoma was rarely to never found in re-excision 
specimens and that there was no association with the number of investigated blocks. 
The histopathological examination of re-excision specimens could be omitted, as the 
examination of one block does not guarantee the detection of residual cells. The 
examination of a single block was chosen as a measure to check for presence of a 
scar, to see if a re-excision of the right lesion had been performed. However, ensuring 
excision of the right lesion can be established by clear communication about the 
localisation of the melanoma between the physician who performed the diagnostic 
excision and the physician performing the re-excision (if they are not the same) and 
instructions to the patient, instead of the – more expensive - pathological evaluation 
of the scar of the diagnostic excision.
Further research is needed to determine if re-excisions can be 
omitted in case of previously completely excised melanomas
We hypothesised that a re-excision can be omitted in some cases, because residual 
melanoma occurs rarely in re-excisions of completely excised melanomas. For 
example, in melanomas ≤1 mm, satellites are less frequently present compared to 
thicker melanomas [22] and the rate of local recurrence is low [23]. To investigate 
whether omitting a re-excision is safe in terms of recurrence- or metastasis-free 
survival, a randomised controlled trial in which patients are randomised to either a 
re-excision or watchful waiting, should be carried out. However, to identify differences 
in local recurrence rates or overall survival, a large number of patients is needed. 
Another problem might be the inclusion of patients as they might prefer a re-excision, 
as this is current standard care. On the other hand, re-excisions can cause large 
mutilating scars, which can be avoided if the re-excision provides no benefit to the 
patient. Advised re-excision margins became smaller over time, since randomised 
studies showed that no differences in disease-free or overall survival occurred, when 
comparing wide (3-5 cm) versus narrow (1-2 cm) margins in thicker melanomas 
[24-32]. Future investigations should assess whether excision margins can also be 
further diminished or even omitted in thin melanoma.
The Netherlands Cancer Registry is a highly valuable data source, 
but would be even more valuable if it included more disease-
specific data 
The Netherlands Cancer Registry (NCR) started in 1989 as a population-based, 
nation-wide registry which could be used to perform epidemiological studies on the 
incidence, mortality and survival of different types of cancer. However, now that the 
data collected by the NCR is also being used for other types of research, for example 
studies on quality of care or disease specific outcomes other than death, the type of 
recorded data is not always sufficient anymore.
 For all studies described in this thesis we used data collected by the Netherlands 
Cancer Registry, for example on demographic characteristics (i.e., gender, age at 
diagnosis and date of death) and tumour characteristics (i.e., date of diagnosis, 
location of the tumour, histology, Breslow thickness). Long-term follow up data on 
local recurrences and disease progression (development of distant metastases) 
would have been useful for some of our studies. For example, in our study on the 
impact of a new TNM classification system, we could have compared the recurrence 
free and overall survival of patients with pT1a and pT1b according to both the 6th and 
7th edition of the TNM staging system, to check if patients are classified more 
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accurately with the new staging system. In our study the number of patients with pT1 
melanoma and the duration of follow-up was limited to make valid comparisons, but 
in the NCR large patient numbers are available. However, in the NCR patients are 
staged according to the staging system that was relevant at the time of diagnosis, 
and it is not feasible to stage tumours according to other systems when certain 
tumour features were not recorded at diagnosis (e.g., mitotic rate).
 In our study on melanoma of unknown primary, we found that the number of 
involved nodes was an important prognostic factor for melanoma of unknown primary 
(MUP) with nodal manifestation. In these patients, the NCR records the site (topography) 
of the primary tumour as C80.9 (primary localisation of tumour unknown) and the 
location of metastases. In patients with multiple nodal metastases, ICD-O-3 code 
C77.8 is often used, which means that ‘lymph nodes of multiple regions’ are involved. 
Although it is clear that with this code, more than one nodal station is involved, it is 
unclear how many and which regions were exactly involved. Therefore, we could only 
compare MUP patients with either one or with more than one nodal metastasis. On 
the other hand, recording all cancer-related data is not feasible and a national cancer 
registry has to find a balance between which information is recorded and which 
information is not. 
To increase research possibilities on familial risk of cancer,  
the Dutch government should allow the use of social security 
number for research purposes
One of our initial research questions was to determine the cumulative risk of melanoma 
in first degree relatives of melanoma patients and to investigate the role of sun-related 
factors in the familial risk of melanoma. Unfortunately, questionnaire data on cancer 
history in first-degree relatives, assessed by the proband, appeared to be aspecific 
and unreliable (data not published). 
 In Nordic countries, family relations are traced by social security numbers and 
can be linked to cancer registries [33-39]. This enabled researchers to perform 
several valid, high powered analyses on different types of research questions, 
including a large study on the familial risk of melanoma [39]. In the Netherlands, 
however, genealogy data is not systematically recorded. Ideally, the government 
would allow the linkage of family relations between citizens through the use of social 
security number and furthermore, linkage to disease registries such as the NCR. 
However, the Dutch law only allows limited linkage of registries, because of privacy 
regulations [40].
The Dutch government should focus on implementation of effective 
primary prevention strategies for melanoma
In the Netherlands, the incidence of melanoma is rising by about 4% yearly and is 
expected to continue rising [41]. Exposure to ultraviolet (UV) radiation is probably one 
of the most important causes of this rise with a Population Attributable Fraction (PAF) 
of melanoma of 0.3-0.9 [42, 43]. Therefore, at least a part of melanoma diagnoses is 
preventable. 
 Nowadays, it seems that many Dutch still do not use adequate protection against 
the sun. In the Netherlands, few studies on cognitions about sun protection and skin 
cancer awareness have been performed. In one Dutch study, only 47.5% of 
adolescents reported to always use sunscreen and seeking shadow was seen as an 
unpopular strategy [44]. In a British survey, people reported that getting a tan was 
important, especially during holidays spent abroad [45]. 
 The Dutch government currently does not employ any skin cancer prevention 
campaigns. In 2014, only the Dutch Cancer Society was broadcasting a video clip via 
social media with the message ‘enjoy the sun, protect your skin’ [46]. Clear, 
unambiguous messages remain a challenge, since UV exposure should not be 
completely avoided due to the beneficial effects of UV-radiation, for example the 
formation of vitamin D [43, 47]. In the 1990s, the ‘freckle bus’ campaign got some 
attention, which was in fact a screening campaign aimed at visitors of Dutch beaches 
[48]. Additional screening efforts were undertaken in a few outpatient clinics in the 
Netherlands [49]. Screening is a form of secondary prevention, and although it may 
increase skin cancer awareness, it does not seem to be cost-effective when focused 
on melanoma alone [50, 51]. Moreover, it is aimed at early detection of skin cancer 
and not on prevention of the cancer itself. 
 Compared to for example a country like Australia, which has the highest 
melanoma incidence in the world [52], the extent of public education on skin cancer 
is low in the Netherlands. In Australia, the increase in melanoma incidence in the 
younger population appears to have stabilised due to public campaigns [53-55]. 
However, a recent study showed that the incidence of melanoma is increasing in 
young susceptible Australians and it is suggested that the reported stabilisation 
might have been caused by immigration of low risk groups [56].
 Still, the Dutch government should focus more on primary prevention of skin 
cancer, and melanoma in particular. The Dutch population needs to be actively and 
continuously educated about the risks of tanning and the use of sun beds. Although 
complete avoidance of sun exposure is not sensible, the risk of vitamin D deficiency 
seems low with normal use of sunscreens [57]. 
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Future studies should investigate cost-effectiveness of all aspects 
of melanoma care (not only cost-effectiveness of new therapies)
Costs of medical care have risen in the last decades, and cost-effectiveness analyses 
have gotten more attention. Especially for expensive therapies applied in advanced 
melanoma, such as immunotherapy and targeted therapies, a number of cost- 
effectiveness studies have been published [58-60]. It can be concluded from these 
studies that these therapies are not cost-effective, but would be if the prices of these 
drugs approached the thresholds for every gained quality adjusted life year (QALY). 
However, some treatment protocols in melanoma lack evidence and we can wonder 
whether these protocols are effective, let alone cost-effective. For example, the 
standard histopathological examinations of re-excision specimens of completely 
excised melanomas do not increase treatment efficacy, but cost approximately α80 
per examination in the Netherlands. Furthermore, there is no evidence for the benefit 
of re-excisions in patients with melanoma in situ, and limited evidence for re-excisions 
in thin melanomas (i.e., with a Breslow thickness ≤ 1 mm) [24]. It would be interesting 
to further investigate whether re-excisions could be omitted in some cases, both from 
an ‘evidence based medicine’ point of view and to spare medical costs. 
 Another example include follow-up schedules: the Dutch guideline advises a 
follow-up of at least 5 years after the diagnosis of a melanoma thicker than 1 mm [7] 
despite the fact that most new events are discovered by patients themselves [61, 62] 
[7]. Also, one can wonder how cost-effective sentinel lymph node biopsies (SLNBs) 
are, since the benefit of this procedure in terms of overall survival remains uncertain. 
Moreover, with respect to the previous paragraph, effective primary prevention 
strategies will likely be cost-effective, as high costs spent on diagnosis and treatment 
of (metastasised) melanoma are spared. 
 With the rising incidence of melanoma and the rising costs of medical care, it is 
important to decide how to spend our money. Therefore future studies investigating 
treatments or diagnostic procedures in melanoma should include cost-effectiveness 
analyses. 
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SUMMARY
Summary
The main objective of this thesis is to increase knowledge on specific epidemiological 
and clinical aspects of cutaneous melanoma, relevant for daily clinical practice. Most of 
the presented studies were performed within a framework of a genome-wide association 
study aiming to find new melanoma susceptibility genes. Patients included in this 
study were all recruited via the Netherlands Cancer Registry (NCR). Clinical data 
were derived from the NCR and in addition, data were collected through medical files 
and questionnaires on general health, lifestyle and melanoma risk factors. In order to 
verify all melanoma diagnoses, a pathology review of primary melanomas was 
performed by an expert dermatopathologist.
Part I  Epidemiological aspects 
 
Few population-based studies have been published on melanoma of unknown 
primary origin (MUP). Therefore a study investigating characteristics and survival of 
patients with MUP using data from the Netherlands Cancer Registry (NCR) is 
described in Chapter 2. In addition, comparisons were made with patients with 
melanoma of a known primary (MKP). For this study, patient and tumour characteris-
tics of patients diagnosed with MUP or MKP between 2003 and 2009 were retrieved 
from the NCR. In total, 2.6% (n=857) of all 33,181 melanoma patients were diagnosed 
with MUP. MUP patients with a single nodal metastasis had a similar survival as MKP 
patients with TNM stage III and a single macroscopic nodal metastasis (2-year 
survival 69% versus 68%). When patients had more than two macroscopic nodal 
metastases, the MUP patients had a worse survival compared to MKP patients 
(2-year survival 23% versus 47%). MUP patients with distant metastases had a similar 
survival as MKP stage IV patients (2-year survival 24% versus 20%). With the 
knowledge from this study, practitioners can offer adequate treatment to patients with 
MUP and better inform them about their prognosis.
Self-reported information on environmental and life-style related risk factors remains 
important in melanoma research. Knowledge about the quality of this information, 
especially when reported by melanoma patients, is scarce. Therefore, the reproducibility 
of questionnaire items on melanoma risk factors was assessed in Chapter 3. Recently 
diagnosed melanoma patients (2008-2011, n=389) were asked to fill out a questionnaire 
on melanoma risk factors twice. Questionnaire items focused on phenotypic 
 characteristics, past sun exposure and sunburn history during child- and adulthood. 
The test-retest reproducibility was assessed by calculating kappas (κ), weighted 
kappas (κw) and intraclass correlation coefficients (ICCs) for categorical, ordinal and 
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continuous variables, respectively. Stratified analyses were carried out by gender, 
age group, education level, and time since diagnosis. We found that the reproducibility 
was ‘substantial’ (according to the categories suggested by Landis and Koch) for 
phenotypic characteristics, ‘fair-to-substantial’ for sun exposure and sun protection 
behaviour, and ‘moderate’ for sunburn history. The reproducibility was slightly better 
in younger patients and patients with a high education. Although these findings do 
not guarantee a high validity, it seems that this type of questionnaire is still useful in 
research settings.
Patients with cutaneous melanoma are at increased risk for second primary melanoma, 
compared to the general population. Knowledge about which patients are at increased 
risk can help clinicians to tailor surveillance schedules to individual patients, but 
relatively few studies have investigated which  factors increase the risk for a second 
primary. Therefore, a study was carried out, described in Chapter 4. Melanoma patients 
with a primary melanoma diagnosed between 2003 and 2011, who completed a 
questionnaire on general health and melanoma risk factors were included (n=1127). 
The number of second primary melanomas was recorded from either medical files or 
the NCR, and multivariable Cox regression analysis was performed to identify risk 
factors for second primary melanomas. A high nevus density was a strong risk factor, 
as was working outside for more than 10 years. Also older age, and having in situ 
melanoma were associated with developing a second melanoma. These findings 
suggest that in addition to phenotypic characteristics, (cumulative) sun exposure 
plays an important role  in the development of second melanomas. We also found 
that the risk of developing a second melanoma was as high in year 5-10 after 
diagnosis (conditional cumulative risk 4.6%) as it is in the first 5 years (cumulative risk 
3.7%). The current guideline does not advise standard follow-up for patients with 
melanoma in situ and a maximum follow-up duration of 5 years for patients with 
melanoma >1 mm. Dermatologists may need to intensify or lengthen follow-up for 
patients with previous in situ melanoma, high cumulative sun exposure and certain 
phenotypic characteristics, such as high nevus density. 
Part II  Clinical aspects
In the transition from the sixth to the seventh edition of the American Joint Committee 
on Cancer (AJCC) melanoma staging system, mitotic activity was added to the 
staging protocol, while Clark’s level of invasion was abandoned. In Chapter 5, we 
described the effect of this change on the substaging of pathological tumour (pT)1 
melanoma, and the possible clinical implications. Patients with pT1 melanoma were 
selected from a population-based cohort study on melanoma. Their pT1 melanomas 
were systematically reviewed by an expert dermatopathologist and classified 
according to the sixth and seventh edition of the AJCC staging system. The shift of 
tumours between pT1 substages was determined, and overall 28% of (57/207) of all 
pT1a melanoma shifted to pT1b when classified according to the seventh staging 
classification. About 32% (17/53) of pT1b melanomas shifted to pT1a. The total 
number of pT1b melanoma increased from 20% to 36%. We concluded that the 
addition of mitotic activity to the pathological staging system results in a considerable 
change in the classification of thin cutaneous melanomas. This change has clinical 
implications, as more patients will be staged as stage IB and thus will be offered a 
sentinel lymph node biopsy (SLNB).
In the latest Dutch melanoma guideline, it is advised to investigate only one central 
block of a re-excision specimen after a complete primary excision. This advise was 
based on only three British studies. In Chapter 6, we retrospectively assessed the 
percentage of residual tumour cells in re-excision specimens of 812 completely 
excised cutaneous melanomas, and found that in only 0.5% residual tumour cells 
were discovered. We concluded that the examination of one block is arbitrary and 
can be omitted, as this is time consuming and not cost-efficient, and finding residual 
tumour has no therapeutical consequences. Moreover, since the prevalence of 
residual tumour is low, these findings even imply that in selected cases, a re-excision 
can safely be omitted. However, additional research is needed to confirm this.
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Het doel van dit proefschrift is het vergroten van kennis omtrent specifieke epidemio-
logische en klinische aspecten van het melanoom van de huid, die relevant zijn voor 
de dagelijkse klinische praktijk. De meeste studies in dit proefschrift zijn onderdeel 
van een genoomwijde associatiestudie, gericht op het vinden van nieuwe risicogenen 
voor melanoom. De patiënten die deelnamen aan deze studie zijn allen benaderd via 
de Nederlandse Kanker Registratie (NKR). Klinische gegevens werden verkregen 
vanuit de NKR. Daarnaast werden aanvullende gegevens verzameld vanuit medische 
dossiers en door vragenlijsten af te nemen over algemene gezondheid, leefstijl en 
risicofactoren voor melanoom. Om de diagnose melanoom te verifiëren werd een 
pathologische revisie verricht van alle primaire melanomen door een gespecialiseerd 
dermatopatholoog.
Deel I  Epidemiologische aspecten
Over melanoommetastasen van onbekende primaire origine (in het Engels melanoma 
of unknown primary, afgekort als MUP) zijn slechts enkele populatiestudies gepubliceerd. 
Daarom hebben wij een studie verricht naar de karakteristieken en overleving van 
patiënten met MUP, waarbij gegevens zijn gebruikt uit de Nederlandse Kanker 
Registratie (NKR). Deze studie is beschreven in Hoofdstuk 2. Er werden vergelijkingen 
gemaakt met patiënten met een melanoom van bekende origine (melanoma of 
known primary, afgekort als MKP). Patiënt- en tumorkarakteristieken van patiënten 
met een MUP of MKP, gediagnosticeerd tussen 2003 en 2009 werden uit de NKR 
verkregen. In totaal had 2,6% (n=857) van alle 33.181 patiënten met een melanoom 
een MUP. MUP-patiënten met een enkele lymfkliermetastase hadden een vergelijkbare 
overleving met MKP-patiënten met een TNM-stadium III melanoom met een enkele 
lymfkliermetastase (2-jaars overleving 69% tegenover 68%). Indien patiënten meer 
dan twee macroscopische lymfkliermetastasen hadden, hadden de MUP-patiënten 
een slechtere overlevingskans vergeleken met de MKP-patiënten (2-jaars overleving 
23% tegenover 47%). MUP-patiënten met afstandsmetastasen hadden een vergelijkbare 
overleving met  MKP- patiënten met TNM stadium IV (2-jaars overleving 24% tegenover 
20%). Met de kennis verkregen in deze studie kunnen artsen de behandeling van 
patiënten met een melanoom van onbekende primaire origine meer toespitsen en 
hen beter informeren over de prognose. 
Zelfgerapporteerde informatie over omgevings- en leefstijlfactoren blijft van belang 
bij het verrichten van onderzoek naar melanoom. Er is weinig kennis over de kwaliteit 
van deze gegevens, vooral wanneer deze gerapporteerd worden door melanoom-
patiënten. Daarom werd de reproduceerbaarheid van vragenlijstitems over risico factoren 
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voor melanoom bepaald in Hoofdstuk 3. Recent gediagnosticeerde melanoom-
patiënten (2008-2011, n=389) werden gevraagd een vragenlijst met daarin vragen 
over risicofactoren tweemaal in te vullen. De vragenlijstitems hielden vragen in over 
fenotypische kenmerken, zonblootstelling en zonverbranding in het verleden. De test- 
hertest reproduceerbaarheid werd bepaald door kappa’s (κ), gewogen kappa’s (κw) 
en intraclass correlation coefficients (ICCs) te berekenen, voor respectievelijk 
categoriale, ordinale en continue variabelen. Gestratificeerde analyses werden 
verricht voor geslacht, leeftijdsgroep, opleidingsniveau en de tijd sinds de diagnose. 
We vonden dat de reproduceerbaarheid ‘substantieel’ was (overeenkomend met 
de categorieën gesuggereerd door Landis & Koch) voor fenotypische kenmerken, 
‘redelijk-tot-substantieel’ voor zonblootstelling en zonbescherming en ‘gemiddeld’ 
voor zonverbranding in het verleden. De reproduceerbaarheid was iets beter bij 
jongere patiënten en bij patiënten met een hoger opleidingsniveau. Hoewel deze 
bevindingen geen hoge validiteit garanderen, lijkt dit type vragenlijsten nog steeds 
van waarde in het onderzoek naar melanoom.
Patiënten met een huidmelanoom hebben, vergeleken met de algemene populatie, 
een hoger risico op het krijgen van een tweede huidmelanoom. Kennis over welke 
patiënten een verhoogd risico hebben kan artsen helpen om nacontroles toe te 
spitsen op de individuele patiënt. Relatief weinig studies hebben echter onderzocht 
welke factoren het risico op een tweede melanoom verhogen. Daarom werd een 
studie hiernaar verricht, beschreven in Hoofdstuk 4. Melanoompatiënten met een 
primair melanoom gediagnosticeerd tussen 2003 en 2011, die een vragenlijst hadden 
ingevuld over algemene gezondheid en risicofactoren voor melanoom werden 
geïncludeerd in deze studie (n=1127). Het aantal tweede primaire melanomen werd 
verkregen uit medische dossiers of de NKR. Een multivariabele Cox-regressieanalyse 
werd verricht om risicofactoren voor een tweede melanoom te identificeren. Een 
hoog aantal moedervlekken was een sterke risicofactor, evenals het hebben van een 
baan buitenshuis gedurende meer dan 10 jaar. Ook was het hebben van een hogere 
leeftijd en het hebben van een in situ melanoom geassocieerd met het ontwikkelen 
van een tweede melanoom. Deze bevindingen suggereren dat, naast fenotypische 
kenmerken, (cumulatieve) zonblootstelling een rol speelt bij het ontwikkelen van 
tweede melanomen. We vonden daarnaast dat het risico op een tweede melanoom 
even hoog was in jaar 5-10 na de diagnose (conditioneel cumulatief risico 4,6%) als 
in de eerste 5 jaar (cumulatief risico 3,7%). De huidige richtlijn adviseert geen 
standaard follow-up voor patiënten met een in situ melanoom en een maximale 
follow-up van 5 jaar voor mensen met een melanoom >1 mm. Dermatologen zouden 
daarom mogelijk nacontroles moeten intensiveren of verlengen voor melanoom-
patiënten met een in situ melanoom, een hoge cumulatieve zonblootstelling en 
bepaalde fenotypische kenmerken, zoals een hoog aantal moedervlekken.
Deel II  Klinische aspecten
Bij de overgang van de zesde naar de zevende editie van het stadiëringssysteem 
voor melanoom van de American Joint Committee on Cancer (AJCC) is de mitotische 
activiteit toegevoegd aan het stadiëringsprotocol, terwijl het Clark niveau van invasie 
volledig is verlaten. In Hoofdstuk 5 beschrijven we het effect van deze verandering 
op de substadiëring van (pathologisch) tumor stadium 1 (pT1) en de mogelijke 
klinische implicaties hiervan. Patiënten met pT1 melanoom werden geselecteerd uit 
een populatiebrede cohortstudie naar melanoom. Van deze patiënten werden de 
melanoomcoupes systematisch gereviseerd door een gespecialiseerd dermato-
patholoog en geclassificeerd volgens zowel de zesde als de zevende editie van het 
AJCC-stadiëringssysteem. De verschuiving van tumoren tussen de pT1 substadia 
werd bepaald. Van alle pT1a melanomen verschoof 28% (57/207) naar pT1b wanneer 
ze werden gestadieerd volgens de zevende editie. Ongeveer 32% (17/53) van de 
pT1b melanomen verschoof naar pT1a. Het totale aantal pT1b melanomen nam toe 
van 20% naar 36%. We concludeerden dat de toevoeging van de mitotische activiteit 
aan het pathologische stadiëringsprotocol een aanzienlijke verandering teweegbracht 
in de stadiëring van dunne huidmelanomen. Deze verandering heeft klinische 
implicaties, aangezien er meer patiënten met een melanoom stadium IB gestadieerd 
zullen worden en dus een schildwachtklierprocedure aangeboden zullen krijgen, 
zoals geadviseerd wordt in de Nederlandse richtlijn.
In de huidige Nederlandse richtlijn wordt geadviseerd om na een radicale primaire 
excisie van een melanoom slechts één centraal blokje van een reëxcisiepreparaat te 
onderzoeken. Dit advies is gebaseerd op slechts drie Britse studies. In Hoofdstuk 6 
hebben wij in een retrospectieve studie onderzocht wat het percentage residuele 
cellen is in reëxcisiepreparaten van 812 compleet verwijderde huidmelanomen. We 
vonden dat slechts 0,5% van de preparaten residuele tumorcellen bevatte. Daarop 
concludeerden we dat het onderzoeken van een enkel centraal blokje arbitrair is, 
omdat het tijdrovend en niet kostenefficiënt is, en daarnaast omdat het vinden van 
residuele cellen geen therapeutische consequenties heeft. Aangezien de prevalentie 
van residuele tumorcellen laag is, kan verondersteld worden dat in bepaalde gevallen 
zelfs de reëxcisie achterwege gelaten kan worden. Echter, om dit te bewijzen is 
aanvullend onderzoek nodig.
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